This invention relates to the health management of animal populations and to a method for the prophyl- 5 actic and curative treatment of parasitic protozoal infec¬ tions in animals, including mammalian and avian species. This invention also relates to the suppression of a partic¬ ular parasitic class of Protozoa, namely Sporozoa, species of which commonly infect the gastrointestinal tract, renal

10 tubules, cecu and liver of animals and, in particular, animals of the avian species.

All members species of the Sporozoan class of Protozoa are parasitic. A particular subdivision of Sporozoa, namely, Coccidia, is of particular interest.

15 This subdivision, includes the genera, Eimeria, Isospora, Klossiella and Hepatozoon, which are responsible for the disease condition known as coccidiosis.

Coccidia species infect chickens, canines, felines, rabbits, cattle, sheep and goats, swine, geese, mice, rats, frogs, guinea pigs and man, among others. Coccidosis affects the living host adversely in many ways ^* depending upon the tissue preference of the particular parasite involved and the number of oocysts in the initial infection. There are as many kinds of coccidiosis as there are species of coccidia, each with its characteristi signs. In many cases, infection may result in the death of the host animal.

Coccidiosis is a disease which starts with the oδcyst, the egg-like form of the parasite. Under favorabl conditions, oocysts sporulate and become infective. In¬ fection can be readily spread throughout an entire pop- ulation of animals, such as, sheep and cattle in a feed lot or pasture, chickens in pens, and, canines and felines, through the release of coccidia oocysts in fecal waste, followed by oδcyst ingestion by uninfected animals.

As a group, the coccidioses of chickens cause more severe financial loss than is encountered in other domesticated avian species. Losses following a severe outbreak may be devastating. Turkeys, geese, ducks and guinea fowl suffer less severely from intestinal cocci¬ diosis infection than do chickens; however, economic losses occur under certain conditions in all these birds.

In spite of recent advances in the prevention and control of coccidiosis through chemotherapy, the disease remains a major problem in the poultry industry. Unlike many other poultry diseases, coccidia are almost universally found wherever chickens are being raised.

The resistant oocysts are readily transported in live birds which sometime remain carriers for long periods of time. Because most coccidial infections are sub- clinical, the poultry producer is usually unaware of the presence of several species of organisms infecting his flock until mismanagement permits an explosive develop¬ ment of a large number of sporulated oocysts.

Of the four genera of Sporozoa mentioned above, the genus Eimeria includes the species of coccidia respon- sible for coccidiosis in chickens. • The nine recognized species of Eimeria reported in chickens are: Eimeria acervulina; Eimeria brunetti; Eimeria hagani; Eimeria maxima; Eimeria mi ati; Eimeria mitis; Eimeria necatrix; Eimeria praecox; and Eimeria tenella. The differential pathological characteristics of infections caused by these species of coccidia are discussed in the article by . Malcolm Reid, entitled, "Coccidiosis", in Diseases of Poultry, Sixth Edition, Iowa State U. Press- (1972). -

REPORTED DEVELOPMENTS

The sulfa drugs were first used to suppress coccidiosis in poultry, but of these drugs only a few are currently being used. Their major disadvantage is that administration of high levels of the drug for ex¬ tended periods of time may result in the development of hemorrhagic syndrome.

Anticoccidal formulations currently used in feed compositions include: sulfaquinoxaline; nitro- furazone; nitrophenide; sulfanitran; arsenobenzene;

a mixture of butynorate, sulfanitran, dinsed, and roxar- sone; nicarbazin; a mixture of nitrofurazone, furazoli- done, bithionol, and methiotriazamine; a mixture of 2,4- diamino-5-(p-chlorophenyl)-6-ethyl-pyrimidine and sulfa- quinoxaline; furazolidine; glycarbylamide; a mixture of nitromide, sulfanitran, and roxarsone; oxytetracycline; amprolium; chlortetracycline; zoalene; a mixture of amprolium and ethopabate; nihydrazone; a mixture of aklomide and sulfanitran; buquinolate; clopidol; deco- quinate; and monensin.

Toxicity is a serious drawback to the use of many of the currently available anti-coccidials, such as, monensin. A variation in dose of as little as 20% can be detrimental, if not fatal, to medicated poultry while a decrease in dose of 20% may result in an ineffect¬ ive therapy. Furthermore, a major problem with anti- coccidial drugs is that the coccidia species may develop drug resistance under conditions of low-level prophylactic use of the anticoccidial compound. Additionally, govern- ment regulations relating to acceptable levels of drug residues in animal tissue destined for human consumption require the withdrawal of the anticoccidial agent in the animals' feed weeks prior to their going to market. Hence, the risk of an outbreak of coccidiosis just prior to slaughter is great.

This invention relates to the discovery that a relatively non-toxic class of ureas and thioureas ex¬ hibits surprisingly effective activity against parasitic sporazoa, and, in particular, is useful in the treatment of coccidiosis.

OMPI. ^" 1FO

SUMMARY OF THE INVENTION

This invention relates to a method for the suppression of coccidial infections in animals comprising administering to an animal exposed to Coccidia an effect¬ ive amount of an a idinourea or amidinothiourea.

Representative compounds found useful in the prophylactic or curative treatment of coccidiosis in populations of animals including infected members comprise an anti-coccidial compound according to Formula I or Formula II

Formula I

Formula II

wherein: X is oxygen or sulfur;

R ,, R ₂ , R ₃ , R-, _ς and R _g are hydrogen, alkyl, cycloalkyl, cycloalkenyl, bicycloalkyl, alkenyl, alkynyl, alkoxy, hydroxy, haloalkyl, haloalkenyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, aminoalkyl, mono- or di- alkyl aminoalkyl, carbamoylalkyl, mono- or di- alkyl carbamoyl

_OMPI_ WIPO

lower alkyl, alkoxy carbamoylalkyl, aralkoxy carbamoyl- alkyl, acyl , alkylsulfonyl, aralkylsulfonyl, aryl, aralkyl, heterocyclyl, substituted heterocyclyl, hetero- cyclylalkyl, or substituted heterocyclylalkyl; R, and R ₂ together with the nitrogen to which they are attached may form a mono- or bicyclic 5 to 10 member heterocycle containing 0 to 4 additional hetero- ato s of oxygen, nitrogen or sulfur;

R _e and R _g together with the nitrogen to which they are attached may form a mono- or bicyclic 5 to 10 member heterocycle, containing 0 to 4 additional hetero- . atoms of oxygen, nitrogen or sulfur;

R. and R _j . together with the nitrogens to which they are attached may form a mono- or bicyclic 5 to 10 member heterocycle, containing 0 to 4 additional hetero- atoms of oxygen, nitrogen or sulfur; provided that at least one of R.. , R_, R_, R., ₅ and R _g is other than hydrogen; and, pharmaceutically acceptable salts thereof. The present invention can be used to particular advantage in the treatment of coccidiosis in avian species, for example, poultry, and encompasses a method of prophy¬ lactic and curative therapy using a pharmaceutical com¬ position, feed mixture or liquid supplement containing one or more amidinoureas or amidinothioureas, including those within the scope of Formulae I and II above.

This invention also relates to pharmaceutical preparations, and feed and liquid compositions, for prophy¬ lactic and curative treatment of coccidiosis utilizing amidinoureas and amidinothioureas.

DETAILED DESCRIPTION OF THE INVENTION

Amidinoureas and amidinothioureas include one of the isomeric structural groups x N" ^"

wherein X is oxygen or sulfur. In any discussion of the true structure of an amidinourea or amidinothiourea, tautomerism must be considered. (For convenience, the term "amidinourea" is hereafter used to encompass amidino-

10 thioureas). Those skilled in the art know that the amidi¬ nourea chain can be legitimately represented in any one of several tautomeric forms. When the amidinourea is in solution, one form may predominate over another depend¬ ing upon the degree and location of substitution and

^•* L5 on the nature of the solvent. The rates of conversion of one tautomer to another will depend upon the nature of the solvent, the degree of hydrogen bonding permitted, the temperature, and possibly other factors (such as pH, trace impurities and the like). o To illustrate what is meant by this, a number of likely structures are here shown for -two • of the compounds of this invention:

_c-?ι_

OMPI

Other structures are also possible, such as those with hydrogen bonding .

Furthermore, the heterocyclic atom may contri¬ bute to structures reflecting hydrogen bonding .

OMPI

As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

"Alkyl" means a saturated aliphatic hydrocarbon which may be either straight- or branched-chain. Preferred groups have no more than about 12 carbon atoms and may be methyl, ethyl and structural isomers of propyl, butyl, pe tyl, hexyl, he tyl, octyl, nonyl, decyl, undecyl and dodecyl. "Lower alkyl" means an alkyl group as above, having 1 to 6 carbon atoms. Suitable lower alkyl groups are methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl and neopentyl.

"Cycloalkyl" means an aliphatic monocyclic saturated carbocyclic group having 3 to 6 carbon atoms. Preferred groups are cyclopropyl, cyclopentyl and cyclo- hexyl.

"Alkenyl" means an unsaturated aliphatic hydro¬ carbon. Preferred groups have no more than about 12 carbon atoms and 1 to 3 carbon double bonds and may in¬ clude straight or branched chains, and may be any struc¬ tural and geometric isomers of ethenyl, propylenyl, bute- nyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, dece- - nyl, undecenyl, and dodecenyl or butadienyl, pentadienyl etc. Also included are the cycloalkylene groups such as cyclopropenyl, cyclopentenyl, cyclohexenyl, etc. and the cycloalkylalkylene groups such as cyclo-propyleneyl- methyl, and cyclohexenylmethyl and the like.

"Lower alkenyl" means alkenyl of 2 to 6 carbon atoms such ethylene, propylene, butylene, isobutylene, etc. _r including all structural and geometrical isomers thereof.

O? PI

"Alkynyl" means an unsaturated aliphatic hydro¬ carbon. Preferred groups have no more than about 12 carbon atoms and contain one or more triple bonds, in¬ cluding any structural or geometric isomers of acetylenyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, etc.

"Lower alkynyl" means alkynyl of 2 to 6 carbon atoms such as structural and geometric isomers of prop- argyl, butynyl, pentynyl, etc. "Aryl" means a substituted or uήsubstituted benzenoid aromatic or a bicyclic aromatic group including phenyl and substituted phenyl.

"Substituted phenyl" or a "substituted benzenoid aromatic or bicyclic aromatic" means a group in which one or more of the hydrogens has been replaced by the same or different substituents including halo, lower alkyl, halo-lower alkyl, nitro, a ino, acylamino, hydroxyl, lower alkoxy, aryl lower alkoxy, acyloxy, cyano, halo- lower alkoxy or lower alkyl sulfonyl. The preferred substituted phenyl group is phenyl in which the 2 and ^' 6 positions are substituted.

"Aralkyl" means an alkyl (preferably a lower alkyl) in which one or more hydrogens is substituted by an aryl moiety (preferably phenyl or substituted phenyl) e.g., benzyl, phenethyl, etc.

"Heterocyclyl" or "heterocycle" means a 3, 5, 6, 7, 8, 9 or 10 member ring having 1 to 5 hetero atoms which may be nitrogen, oxygen or sulfur, including, among others, pyridyl, pyrimidyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, thiazolyl, piperidyl, orpho- linyl, oxazolidinyl, thiazolidinyl, pyrazolodinyl, imidazolidinyl, piperazinyl, thiamorpholinyl, -tri ethyl- enetriaminyl and ethyleneiminyl; where the heterocycle

OMPI

may be mono-, di-, tri- or tetra- substituted by lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, halo, nitro, cyano, sulfonyl, hydroxyl, carboxyl, lower alkanoyl, lower carboalkoxy, lower alkoxy, aryl lower alkoxy, halo lower alkoxy, amido, amino, lower alkylamino, dialkyl- amino, lower alkoxyamino, and aralkylamino.

"Substituted heterocyclyl" means a heterocycle . in which one or more of the hydrogens on the ring carbons have been replaced by substituents as given above with respect to substituted phenyl.

The terms "halo" and "halogen" include all four halogens; namely, fluorine, chlorine, bromine and iodine. The halo alkyIs, halophenyl and halo-substituted pyridyl include groups having one or more halosubstit- uents which may be the same or different such as tri- fluoromethyl, l-chloro-2-bromo-ethyl, chlorophenyl, 4- chloropyridyl, etc.

"Acyloxy" means an organic acid radical of a lower alkanoic acid or aromatic acid such as acetoxy, propionoxy, benzoyloxy, and the like.

"Acyl" means an organic radical of the formula RCO where R is alkyl or aromatic, such as, lower alkanoyl and aroyl. Exemplary acyl groups are acetyl, benzoyl, napthoyl, etc. "Lower alkanoyl" means the acyl radical of a lower alkanoic acid such as acetyl, propionyl, butyryl, valeryl, stearoyl, and the like.

"Alkoxy" is intended to ^■ include hydroxy alkyl groups, preferably lower alkyl groups such as methoxy, ethoxy, n-propoxy, i-propoxy, and the like.

The preferred "aralkyl" groups are benzyl and phenethyl.

OMPI

The preferred "halo lower alkyl" group is tri- fluorometh l.

The preferred "halo lower alkoxy" group is trifluoromethoxy. Among the amidinoureas or thioureas according to Formulae I and II, a preferred group of compounds suitable for use in the practice of this invention are compounds in which at least one of the R, and R ₅ substi- tuents is aryl, aralkyl, heterocyclyl, heterocyclylalkyl, substituted heterocyclyl or substituted heterocyclylalkyl.

A preferred subclass of amidinourea compounds according to Formulae I or II includes those wherein R, or R-. is aryl or aralkyl.

A particularly preferred subclass of these compounds is represented by Formulae III and IV below:

wherein: X is oxygen or sulfur; ° n is 0, 1, 2 or 3; R', is phenyl, substituted phenyl, heterocyclyl or heterocyclyl having one or more of the ring hydrogens replaced by lower alkyl, lower alkoxy, halo, halo lower alkyl, amino, acylamino, acyloxy, aryl lower alkoxy, halo lower alkoxy, nitro, hydroxy, cyano, carboxyl or lower alkyl sulfonyl; and R ₂ , R ₃ , R^, R ₅ and _g are hydrogen, lower alkyl, lower alkoxy, lower alkenyl, cycloloweralkenyl, hydroxy, cycloloweralkyl, aryl, arloweralkyl, heterocyclyl, heterocyclyl lower alkyl, lower alkynyl, halo alkyl,

OMPI

hydroxy lower alkyl, lower alkoxy lower alkyl, cyano lower alkyl, amino lower alkyl, mono- or di- lower alkyl amino lower alkyl, carbamoyl lower alkyl, mono- or di- alkyl carbarooyl lower alkyl, lower alkoxy carbamoyl lower alkyl, aralkoxy carbamoyl lower alkyl, lower alkylacyl, alkyl sulfonyl or aralkyl sulfonyl; or

R_ together with R _g and the nitrogen to which R ₅ and R _g are attached or R ₅ together with R ₃ and the nitrogens to which they are attached may form a 5, 6, 7 or 8 membered heterocyclic ring which may include 0 to 2 additional hetero atoms which may be either oxygen, nitrogen or sulfur; and pharmaceutically acceptable salts thereof;

wherein: X is oxygen or sulfur; n is 0, 1, 2 or 3; ' _g is phenyl, substituted phenyl, heterocyclyl or heterocyclyl having one or more of the ring hydrogens replaced by lower alkyl, lower alkoxy, halo, halo lower alkyl, amino, acylamino, acyloxy, aryl lower alkoxy, halo lower alkoxy, nitro, hydroxy, cyano, carboxyl or lower alkyl sulfonyl; and R-, R , R_, R. and ₅ are hydrogen, lower alkyl, lower alkoxy, lower alkenyl, cyclo lower alkenyl,

OMPI ^' ' ^{' '}

hydroxy, cycloloweralkyl, aryl, arloweralkyl, heterocyclyl, heterocyclyl lower alkyl, lower alkynyl, halo alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, cyano lower alkyl, amino lower alkyl, mono- or di- lower alkyl amino lower alkyl,- carbamoyl lower alkyl, mono- or di- alkyl carbamoyl lower alkyl, lower alkoxy carbamoyl lower alkyl, aralkoxy carbamoyl lower alkyl, lower alkylacyl, alkyl sulfonyl or aralkyl sulfonyl; or, R, together with R ₂ and the nitrogen to which they are attached or R^ together with R ₄ and the nitrogen to which they are attached or R, together with R_ and the nitrogen atoms to which they are attached, may form a 5, 6, 7 or 8 membered heterocyclic ring which may include 0 to 2 additional hetero atoms which may be either oxygen, nitrogen or sulfur; and pharmaceutically acceptable salts thereof. Preferred compounds within this subclass of amidinoureas include those according to Formulae V and - VI.

O. rl

where in : n is 0 , l, 2 or 3 ;

Ra, R. , Re. Rd, and Re are selected from the group including hydrogen, halo, alkyl, alkenyl, cyclo¬ alkenyl, cycloalkyl, alkoxy, hydroxy, cyano, amino, acyl, nitro, acyloxy, haloalkyl, alkoxyalkyl, aminoalkyl, aryl- alkoxy, haloalkoxy, alkylsulfonyl and acylamino; and, X, R,, R , R_, R,, R_ and R _g are as defined above.

A further class of preferred amidinoureas useful in the practice of this invention includes compounds according to Formulae I and II wherein one of the R, or R _e substituentsis an ortho-substituted phenyl group.

A preferred series of compounds within this subclass are described according to Formulae VII and VIII.

wherein: X is oxygen or sulfur; m is 0, 1, 2 or 3;

R, _a , and are hydrogen, lower alkyl, halo, cyano, lower alkoxy, nitro, amino or halo lower alkyl;

^R 2' ^R 3' ^R 4 ^an( ^ ^R 5 ^{are n} y- ^ro 9 ^en f lower alkyl, lower alkoxy, or halo lower alkyl;

R _g is lower alkyl, lower alkoxy, halo lower alkyl, heterocyclyl or heterocyclyloweralkyl; provided that at least one of R or R is other than hydrogen; and pharmaceutically acceptable salts thereof.

wherein: X is oxygen or sulfur; i is 0, 1, 2 or 3;

R, R and R are hydrogen, lower alkyl, halo, cyano, lower alkoxy, nitro, amino or halo lower alkyl;

R,, R_, R. and R^ are hydrogen, lower alkyl, lower alkoxy, or halo lower alkyl;

R ₂ is lower alkyl, lower alkoxy, halo lower alkyl, heterocyclyl or heterocyclyl lower alkyl; provided that at least one of R or R is other than hydrogen; and pharmaceutically acceptable salts thereof. Another preferred subclass of amidinoureas and thioureas for use in the present invention includes compounds according to Formulae I or II, wherein at least one of R, and R_. is heterocyclyl, heterocyclylalkyl, substituted heterocyclyl or substituted heterocyclylalkyl. Exemplary heterocyclyl groups include 1-pyrrole, 2-pyrrole, 3-pyrrole, 2-furan, 3-furan, 2-thioρhene, 3-thiophene, 2-tetrahydrothiophene, 3-tetrahydrothiophene, 1-imidazole, 2-imidazole, 4-imidazole, 5-imidazole, 2- oxazole, 4-oxazole, 5-oxazole, 2-thiazole, 4-thiazole, 5-thiazole, 1-pyrazole, 3-pyrazole, 4-pyrazole, 5-pyrazole, 1-pyrrolidine, 2-pyrrolidine, 3-pyrrolidiήe, l-(3-pyrro- line), 2-(3-pyrroline) , 3-(3-pyrroline) , 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidine, 4-pyrimidine, 5-pyri- midine, 6-pyrimidine, 2-purine, 6-purine, 8-purine, 9-purine, 2-guinoline, 3-quinoline, 4-quinoline, 5-quino-

line, 6-quinoline, 7-quinoline, 8-quinoline, 1-isoquinσ- line, 3-isoquinoline, 4-isoquinoline, 5-isoquinoline, 6-isoquinoline, 7-isoquinoline, 8-isoquinoline, or carbazole; where said heterocycle may be mono-, di-, tri- or tetra-substituted by ring substituents, such as, hydrogen, lower alkyl, lower alkenyl, aryl, lower alkynyl, aralkyl, halo, nitro, cyano, sulfonyl, hydroxyl, carboxyl, lower alkanoyl, lower alkoxy, aryl lower alkoxy, halo lower alkoxy, amido, amino, lower alkylacyloxy, alkylamino, lower alkoxyamino, and aralkoxyamino.

Particularly preferred compounds according to Formulae I to IV are those compounds wherein at least one of R, and R _ς is pyridyl, substituted pyridyl, pyri- dylalkyl or substituted pyridylalkyl, thiophenyl or substituted thiophenyl, thiophenylalkyl or substituted thiopheπylalkyl, pyrrole or substituted pyrrole, pyrrole¬ alkyl or substituted pyrrolealkyl; and the N- or S-oxides thereof. In the substituted heterocyclyl groups, the preferred positions of substitution are the positions vicinal to the heterocyclyl attachment to the amidinourea or thiourea chain.

A subdivision of the various subclasses of compounds defined above which are useful in the practice of this invention are compounds wherein R→. is hydrogen. The presence of hydrogen in the R_ position permits extensive tautomerism throughout the amidinourea chain.

Suitable amidinoureas for use as anti-coccidial agents are also disclosed: in Arzneimittel Forschung, 28(11), 1433-1480 (1978); in U.S. Patent Nos.: 4,115,647; 4,088,785; 4,025,652; 4,115,564; 4,060,635; 4,246,409; 4,058,557 and 4,147,804; and in copending U.S. Patent

0-/?l

/,, WIPO

applications, each assigned to the assignee of the present application , Serial Nos. 262,808, 262,811, 140,135, and , attorney docket no. 10,520, filed in the united States as a PCT application on the same day (August 24, 1981) as the present application, the disclosures of which are incorporated herein by reference. The afore¬ mentioned pending applications and other publications also disclose methods for preparing amidinoureas.

The nomenclature used for compounds useful in the practice of this invention is as follows.

The urea nitrogens are designated as positions 1 and 3. It should be understood that alternate nomenclature can be used to adequately describe the compounds of this invention, one such system of nomenclature being based on the quanidine structure, NH

I I! I

-N-C-N-

Representative examples of compounds useful in this invention are listed below in Tables I, I-A and 2.

TABLE I

l-(2-bromo,6-methylphenyl)-3-n-propylamidinourea l-(2-chloro,6-methylphenyl)-3-ethylamidinourea

1-(2-chlorophenyl)-3-ethylamidinourea l-(2,6-dimethylphenyl)-3-[ (2-pyridylmethyl)amidino]urea l-(2-chloro-6-methylρhenyl)-3-[ (2' ,2' ,2'-trifluoroethyl)- amidino]urea l-(2,6-dimethylphenyl)-3-methylamidinourea

1-(2,6-dimethylphenyl)-3-(3-methylbutoxy)amidinourea l-(2,6-dimethylphenyl)-3-n-propylamidinourea

O-chlorophenylamidinourea

(2,3-dic lorophenylamidino) rea

(2, -dichlorophenylamidino)urea

(2,5-dichlorop enylamidino)urea l-(2 _/ 6-dime h lphenyl)-3-(l' ,1* ,3* ,3'-tetramethylamidino)- urea

1-(2-bromo-6-methylphenyl)-3- (1* ,1' ,3' ,3'-tetramethyl¬ amidino)urea

(3,4-dichlorophenylamidino)urea (3,5-dichlorophenylamidino)urea

(2,6-dichlorophenylaιnidino)urea la-chlorophenylamidinourea p-chlorophenylamidinourea

3,4-difluorophenylamidinourea m-bromophenylamidinourea p-bromop enylamidinourea

3,4-dibromophenylamidinourea

3-chloro-4-bromophenylamidinourea

3-bromo-4-chlorophenylamidinourea 3-chloro-4-fluorophenylamidinourea

3-bromo-4-fluorophenylamidinourea

3-fluoro-4-chlorophenylamidinourea

2,6-dime hylphenylamidinourea

2,6-diethylphenylamidinourea 2-methyl-6-ethylphenylamidinourea

2-methyl-6-methoxyphenylaι_ιidinourea

2-methyl-6-ethoxyphenylamidinourea

Table I (continued)

2-ethyl-6-ethoxyphenylamidinourea

3,4-dimethoxyphenylamidinourea

3,4-dihydroxyphenylamidinourea 3,4,5-trimethoxyphenylamidinourea

3,4,5-trihydroxyphenylamidinourea

1-(2,6-dimethylphenylamidino)-3,3-(N-me h l-3'-azapenta- methylene)urea

1-(2 ,6-dimethylphenylamidino)-3,3-(_N-methy1-3'-azahexa- ethylene)urea

1-(2,6-dime hylphenylamidino)-3,3-(3'-oxapenta ethylene) urea

1-(2,6-dimethylphenylamidino)-3,3-(2, *-thiatetramethylene) urea 1-(2,6-dimethylphenylamidino)-3,3-tetrame hyleneurea

1-(p-fluorophenylamidino)-3,3- (= ^* , ^~ < '-dimethylpenta- ethylene)urea

1-(2,6-dime hylphenylamidino)-3,3'- (•=^,<=^ ^, -dimethylpenta- methylene)urea l-(2,6-dime hylphenylamidino)-3,3-(pentamethylene)urea

1-(2,6-dime hylphenylamidino)-3,3-(<= -methylpentamethylene) urea

1- (N-me hylamidino) -3- (2 , 6-dimethylp enyl) urea

1- (N-methylamidino) -3- (2 , 6-diethylphenyl) rea l-amidino-3- (2-methyl-6-chlorophenyl) urea l-amidino-3- (2-methyl-6-bromophenyl) urea l-amidino-3-(2-methyl-6-methoxyphenyl)urea l-amidino-3-(2,6-dimethylphenyl)urea l-amidino-3-(2-methyl-6-ethylphenyl)urea l-amidino-3- (2-ethyl-6-chlorophenyl)urea l-amidino-3-(2,6-diethylphenyl) rea l-amidino-3-n-ιethyl-3-(2-methyl-6-chlorophenyl)urea l-amidino-3-methyl-3-(2-methyl-6-bromophenyl)urea l-amidino-3-methyl-3-(2-me h l-6-met_hoxyphenyl)urea l-amidino-3-methyl- (2 , 6-dimethylphenyl) urea l-amidino-3-methyl-3- (2-methyl-6-ethylphenyl) urea l-amidino-3-methyl-3- (2-ethyl-6-chlorophenyl) rea ^

Table I (continued)

l-amidino-3-methyl-3-(2-ethyl-6-bromophenyl)urea l-amidino-3-met yl-3-(2-ethyl-6-methoxyphenyl)urea l-amidino-3-meth l-3- (2,6-diethylphenyl)urea l-amidino-3-(2-methyl-6-chlorophenyl)urea l-amidino-3-(2-methyl-6-bromophenyl)urea l-amidino-3-(2,6-dimethyl-4- ydroxyphenyl) rea l-amidino-3-(2,6-dime h l-3-hydroxyphenyl)urea l-amidino-3-(2,6-dimethyl-3, -dihydroxyphenyl)urea l-amidino-3-(2,6-dimethyl-3,4,5-trihydroxyphenyl)urea l-amidino-3-(2,6-dime hy1-4-methoxyphenyl)urea l-amidino-3-(2,6-dimethyl-3-methoxyphenyl)urea l-amidino-3-(2,6-dime h 1-3,4-dimethoxyphenyl)urea l-amidino-3-(2,6-dimethyl-4-ethox phenyl)urea l-amidino-3-(2,6-dimethyl-3,4-diethoxyphenyl)urea

1-(2,6-dimethyl-4-hydroxyphenyl)-3-me hylamidinourea 1-(2,6-dime hyl-3-hydroxyphenyl)-3-methylamidinourea 1—(2,6-dimethyl-3,4-dihydroxyphenyl)-3-methylamidinourea. 1-(2,6-dimethyl-4-methoxyphenyl)-3-methylamidinourea 1-(2,6-dimethyl-3-methoxyphenyl)-3-methylamidinourea

1-(2,6-dimethyl-3,4-dimethoxyphenyl)-3-methylamidinourea 1-(2,6-dimethyl-4-ethoxyphenyl)-3-methylamidinourea 1-(2,6-dimethyl-3-ethoxyphenyl)-3-methylamidinourea 1-(2,6-dime hy1—3,4-diethoxyphenyl)-3-methylamidinourea l-amidino-3-(2,6-dime h lphenyl)urea l-amidino-3-(2-methyl-6-ethylphenyl)urea l-amidino-3-(2-ethyl-6-chlorophenyl)urea l-amidino-3-(2-ethyl-6-bromophenyl)urea l-amidino-3-(2-ethyl-6-methoxyphenyl)urea l-amidino-3-(2,6-diethylphenyl)urea l-amidino-3-methyl-3-(2-methyl-6-chlorophenyl)urea l-amidino-3-me hyl-3-(2-methyl-6-bromophenyl)urea l-amidino-3-methyl-3-(2-methyl-6-methoxyphenyl)urea l-amidino-3-methyl-3-(.2,6-dimethylphenyl)urea l-amidino-3-meth l-3- (2-methyl-6-eth lphenyl) rea l-amidino-3-methyl-3-(2-ethyl-6-chlorophenyl)urea l-amidino-3-me h l-3- (2-ethyl-6-brornophenyl)urea

Table I (continued)

l-amidino-3-methyl-3-(2-ethyl-6-methoxyphenyl)urea l-amidino-3-methyl-3-(2,6-diethylphenyl)urea 1-(2,6-dichlorophenylamidino)-3-n-propylurea 1-(2,6-dimethylphenyl)-3-(isopropylaridino)urea

1-(4-bromo-3-chloro-6-methylphenyl)-3-methylamidinourea 1-(2-bromo-6-me hylphenyl)-3-methylamidinourea 1-(2,6-dimethylphenyl)-3- (N-methyl-N*-propylamidino) rea l-adamantyl-3-ethylaιαidinourea 1-phenyl-l-(2-pyridyl)-3-ethylamidinourea 1- (- -napthyl)-3-ethylamidinourea l-ethyl-3- (-- ^" -napthyl}amidinourea

OMPI

Table I (continued)

1- 2-pyridyl -3— methylamidinourea 1- 2-pyridyl -3-e hylamidinourea

1- 2-pryidyl -3-propylamidinourea

1- 2-pyridyl -3-i-propylamidinourea

1- 2-ρyridyl -3-butylamidinourea

1- 2-pyridyl -3-i-butylamidinourea

1- 2-pyridyl -3-pentylamidinourea 1- 2-pyridyl -3-propargylamidinourea

l- 2-pyridyl -3-allylamidinourea

1- 2-pyridyl -3-methoxy ethyl amidinourea 1- 2-pyridyl -3-benzyloxyethylamidinourea 1- 2-pyridyl -3-phenethoxyethylamidinourea 1- 2-pyridyl -3- (N ,N-dimethylamidino) urea 1- 2-pyridyl -3- (N ,N-diethylamidino) urea 1- 2-pyridyl -3— (N,N— tetramethyleneamidino) urea 1- 2-pyridyl -3- (N ,N-pentamethyleneamidino) urea 1- 2-pyridyl -3- (N ,N-hexamethyleneamidino) urea 1- 2- [3-methylpyridyl] -3-me hylamidinourea 1- 2- [3-me hylpyridyl] -3-ethylamidinourea 1- 2- 13 -me hy lpyr idyl] -3-propylamidinourea 1- 2- [ 3-methylpryidyl] -3-i-propylamidinourea 1- 2- [ 3-me hylpyridyl] -3-i-butylamidinourea 1- 2- I 3 -me thy lpyr idyl] -3-pentyla idinoύrea 1- 2- [3-methylpyridyl] -3-allyl amidinourea 1- 2- [3-me hylpyridyl ] -3-propargyl amidinourea 1- 2- [3-πιethylpyridyl ] -3-cyclopropyl amidinourea 1- 2- [ 3-methylpryidyl]' -3- ethoxyethylamidinourea 1- 2- [3-methylpyridyl] -3 -benzyloxyethylamidinourea

Table I (continued) l-(2-[3-methylpyridyl])-3- (N,N-tetramethyleneamidino)urea ' i-(2-[3-methylpyridyl])-3-.(N,N-pentamethyleneamidino)urea 1-(2-I3-chloropyridyl])-3-methylamidinourea 1-(2-[3-chloropyridyl]) -3-ethylamidinourea 1-(2-[3-chloropyridyl])-3-propylamidinourea 1-(2-[3-chloropyridyl])-3-i-propylamidinourea 1-(2-[3-chloropyridyl])-3-butylamidinourea l- ₍ 2-l3-chloropyridyl])-3-i-butylamidinourea 1-(2-[3-chloropyridyl] )-3-t-butylamidinourea l-(2-[3-chloropyridyl])-3-pentylamidinourea 1-(2-[3-chloropyridyl] )-3-allylamidinourea 1-(2-[3-chloropyridyl] )-3-propargylamidinourea 1-(2-[3-chloropyridyl])-3-cyclopropylamidinourea 1-(2-[3-chloropyridyl])-3-cyclobutylamidinourea

1-(2-[3-chloropyridyl]).-3-cyclopropylmethylamidinourea l-(2-[3-chloropyridyl])-3-π.ethoxyethylamidinourea l-(2-[3-chloropyridyl])-3-benzyloxyeth lamidinourea l-(2-[3-chloropyridyl])-3-phenethoxyethylamidinourea l-(2-[3-chloropyridyl])-3-benzylamidinourea l-(2-[3-chloropyridyl])-3-(N,N-dimethylamidino) rea l-(2-[3-chloropyridyl] )-3- (N,N-diethylamidino)urea

1-(2-pryidyl)-3- ⁽ N,N[3 -oxapentamethylene]a idino)urea

1- ⁽ 3-pyridyl ⁾ -3-methylamidinourea

1- ⁽ 3-pyridyl)-3-ethylamidinourea 1- ⁽ 3-pyridyl ⁾ -3-propylamidinourea 1- ⁽ 3-pyridyl ⁾ -3-i-propylamidinourea 1- ⁽ 3-pyridyl)-3-butylamidinourea 1- ⁽ 3-pyridyl)-3-i-butylamidinourea

Table I (continued)

-3- -butylamidinourea

-3-pen ylamidinourea

-3-allylamidinourea

-3-propargylamidinourea

-3-cyclobutylamidinourea

-3-cyclohexylamidinourea

-3-benzylamidinourea

-3- ethoxyeth lamidinourea

-3-benzyloxyethylamidinourea

-3-me hoxye hylamidinourea

-3-benzyloxye hylamidinourea

-3-phenethoxyethylamidinourea

-3- (N,N-diethylamidino)urea

-3-( ,N-dimethylamidino)urea

-3-(N/N-pentamethyleneamidino)urea

-3-me hylamidinourea

-3-ethylamidinourea

-3-propylamidinourea

-3-i-propylamidinourea

-3—b ylamidinourea

-3-t-b ylamidinourea

-3-pentylamidinourea

-3-hexylamidinourea

-3-propargylamidinourea

-3-allylamidinourea

-3-me hoxyethylamidinourea

-3-benzyloxyethylamidinourea -3- henethoxye h lamidinourea

1-(4-pyridyl)-3-(N,N-tetramethyleneamidino)urea l-( -pyridyl)-3- (N,N-pentamethyleneamidinα)urea l-(4-pyridyl)-3-(N,N-hexamethyleneamidino)urea l-(4-[2-ethylpyridyl])-3-methylamidinourea l-(4-[2-ethylpyridyl])-3-ethylamidinourea 1-( -[2-ethylpyridyl] )-3-propylamidinourea 1-(4-[2-ethylpyridyl])-3-butylamidinourea 1-(4-[2-ethylpyridyl])-3-i-butylamidinourea 1-(4-[2-ethyIpyridyl])-3-pentylamidinourea

1-(4-[2-ethylpyridyl] )-3-allylamidinourea l-(4-[2-ethylpyridyl])-3-propargylamidinourea

1-(4-[2-ethyIpyridyl] )-3-methoxyethylamidinourea

1-(4-[2-ethylpyridyl] )-3-benzyloxyethylamidinourea 1-(4-[2-ethylpyridyl] )-3- (N _/ N-dimethylamidino)urea

1-(4-[2-ethylpyridyl])-3- ( ,N-diethylamidino ^" )urea l-(4-[2-ethylpyridyl] )-3- (N _/ N-tetramethyleneamidino)urea l- ₍ 3[2,4-dimethylthiophenyl])-3-amidinourea

1-(3[2-chloro-4-me hy1 hiophenyl]) -3-m thylamidinourea l-(4-[2,6-dichloropyridyl] )-3-methylamidinourea

1-(4-[2,6-dimethyIpyridyl])-3-methylamidinourea

1-(4-[2-methyl -6-chloropyridyl])-3-methylamidinourea

1-(2-thiophenyl)-3-methylamidinourea

1-(3-thioρhenyl)-3-methylamidinourea 1-(2-[3-methy1thiophenyl] )-3-methylamidinourea •l-(2-[3-chlorothiophenyl] )-3-methylamidinourea 1-(2-pyridyl-N-oxide)-3-(N,N-dimethylamidino)urea l-(2-[3-cyanopyridyl])-3- ^" ethylamidino urea 1-(2-[3-carbomethoxypyridyl]) ^' -3- methylamidino urea l-(2-[3-carboethoxypyridyl))-3- methylamidino urea l-(2-[6-chloropyridyl])-3- methylamidino urea

Table I (continued)

1- 3- [2-me thy Ipyridyl ] ) -3- methylamidino urea 1- 3- [ 2-ethy lpyr idyl ] ) -3- -methylamidino urea

1- 3- [ 2, -dime th Ipyridyl] ) -3- methylamidino urea 1- 2- [3-cyano thiophenyl ] ) -3- methylamidino urea 1- 2- [3-carbomethoxy hiophenyl ] ) -3- methylamidino urea 1- 2- [3-carboethoxy thiophenyl] ) -3- ethylamidino urea 1- 3- [2-me hoxypyridyl] ) -3- methylamidino urea 1- 3- [2-ethoxypyridyl] ) -3- methylamidino urea 1- 3- [2-chloropyridyl] ) -3- -methylamidino urea 1- 2-furyl) -3-amidinourea 1- 3-furyl) -3-amidinourea 1- 2- [3-meth lfuryl] ) -3-amidinourea 1- 2-furyl) -3- ethylamidino urea 1- 2-furyl) -3- propyiamidino urea 1- 2-furyl) -3- i-propylamidino urea 1- 2-f uryl) -3- butylamidino urea 1- 2-furyl) -3- i-butylamidino urea 1- 2-furyl) -3- sec-butylamidinc urea 1- 2-furyl) -3- t-butylamidino urea 1- 2-furyl) -3- -pentyla idino urea 1- 2-furyl) -3- hexylamidino urea 1- 2-furyl) -3- heptylamidino urea 1- 2-furyl) -3- cyclopropylamidino urea 1- 2-furyl) -3- cyclobutyla idino urea 1- 2-pyridyl-N-oxide) -3 -me hy lami inourea 1- 3-pyricyl-N-oxide) -3-methylamidinourea 1- 4-pyri≤yl-N-oxide) -3-me thy lamidinourea 1- 2-furyl) -3-ιπethylamidinourea

Table I (continued)

1-(1-imidazolyl)-3-methylamidinourea 1-(2-imidazolyl)-3-methylamidinourea 1-(4-imidazolyl)-3-methylamidinourea 1-(2-oxazolyl)-3-methylamidinourea 1-(4-oxazolyl)-3-methylamidinourea 1-(5-oxazolyl)-3-methylamidinourea 1—(1-pyrazolyl)-3— ethylamidinourea 1-(1-[3-pyrrolidyl)-3-methylamidinourea 1-(2-pyrrolyl)-3-methylamidinourea 1-(1-morρholinyl)-3-methylamidinourea 1-(2-morpholinyl)-3-methyl midinourea 1-(2-pyrimidinyl) -3-methylamidinourea 1-(4-pyrimidinyl)-3-methylamidinourea 1-(2-quinolinyl)-3-methylamidinourea 1-(4-quinolinyl)-3-methylamidinourea 1-(1-isoquinolinyl)-3-methylamidinourea 1-(2-furyl)-3- cyclopentylamidino urea

1-(2-furyl)-3- cyclohexylamidino urea 1-(2-furyl)-3- phenylamidino urea 1-(2-furyl)-3- benzylamidino urea 1-(.2-furyl)-3- phenethyla idino urea 1- (2-furyl)-3-(N-methyl-N-benzylamidino)urea 1-(2-furyl)-3-(N,N-dibenzylamidino)urea 1-(2-tetrahydrofuryl)-3-amidinourea 1-(2-[3-methyItetrahydrofuryl] )-3-amidinourea 1-(3-tetrahydrofuryl)-3-amidinourea 1-(3-[2-methyItetrahydrofuryl] )-3-amidinourea 1-(1-imidazolyl)-3-amidinourea

OMPI

1-(2-[3-pyrrolino]amidino)urea ^•

1-(1-[2-methyl-3-pyrrσlino]amidino)urea

1-(1-[3-methy1-2-pyrrolino]amidino) urea

1-(1-pyrrolidinoamidino)urea 1-(1-[2-methylpyrrolidxno]a idino)urea

1-(2-pyrrolidinoamidino)urea

1-(2-[1-me hylpyrrolidino]amidino)urea l-(l-morpholinoamidino) urea

1-(1-[2-me hyImorpholino]amidino) urea 1-(2-κιorpholinoa_midino)-.urea

1-(2-[1-meth lmorpholino]amidino) urea

1-(2-[3-methyImorpholino3amidino) urea

1-(1-[3-meth Imorpholino]amidino) urea

1—(3-morpholinoamidino) urea 1-(3-[1-meth Imorphol no]amidino) urea 1-(3-[2-methyImorpholino] amidino) urea

1-(2-pyrimidinόamidinoJu ea

1-(2-[4-methylpyrimidino]amidino) urea

1—(4-pyrimidinoamidino)urea 1-(4-[2-methyIpyrimidino]amidino)urea 1—(2-quxnolinoamidino)urea l-(2-[3-me hylquinolino]amidino) urea 1-(4-σuinolinoamidino)urea l-(4-[2-me hylquinolino]amidino)urea l-(4-[3-methylquinolino]amidino)urea 1-(l-isoquinolinoamidino)urea

T _m ab _.l-e-3I1-(,continued)

3-(2-furylamidino)-1- cyclopentylurea 3-(2-furylamidino)-1-cyclohexylurea 3-C2-f rylamidino)-1-phenylurea 3-(2-furylamidino)-1-benzylurea 3-(.2-furylamidino)-1-phenethylurea

3-(2-furylamidino)-1-(N-methyl-N-benzyl)urea 3-(2-furylamidino)-1- (N,N-dibenzyl)urea

1-(2-tetrahydrofurylamidxno)urea

1-(2-[3-me hyl etrahydrof ryl]amidino) urea 1-(3-tetrahydrofurylamidino) urea

1-(3-[2-methyl etrahydrof ryl]amidino) urea

1-(l-imidazoalamidino) urea

1-(1-[2-me hylimidazoal3amidino) urea 1- (4-imidazoalamidino)urea -(4-[1-methylimidazoal]amidino) urea

1-(4-[2-methylimidazoal] midino)urea

1-(2-imidazoalamidino) urea l*-(2-oxazoalamidino) urea

1—(2-[4-methyloxazoal]amidino)urea H—(4-oxazoalamidino) urea

1_(4-[2-methyloxazoal]amidino)urea

1 -(5-oxazoalamidino) urea

1—(5-[2-methyloxazoal]amidino)urea

1-(4-thiazoalamidino) urea 1—(4-[5-methylthiazoal3amidino) rea

1-(5-thiazoalamidino) urea

1-(5-[4-methylthiazoal] midino)urea

1 -(1-ρyrazoalamidino) urea

a e con nue

3-(2-furylamidino)-1- heptylurea ^• 3-(2- urylamidino)-l- cyclopropylurea 3-(2- rylamidino)-1- cyclobutylurea 3-(2-pyridyl-N-oxideamidino)-1-methylurea 5 3-(2-pyridyl-N-oxideamidxno)-1-methylurea 3-(4-pyridyl-N-oxideamidxno)-1-methylurea 3-(2- urylamidino)-1-methylurea 3-(3-furylamidino)- _" -1-methylurea 3-(2- ^* tetrahydrofurylamidino)-1-methylurea

^• ]0 3-(3-tetrahydrofurylamidino)-1-methylurea 3--{l-imidazoalamidino)-1-methylurea

3- (2-imidazoalamidino)-i-methylurea

3-(4-imidazoalamidino)-1-methylurea

3-(2-oxazoalamidino)-1-methylurea

15 3-(4-oxazoalamidino)-1-methylurea . 3—(5-oxazoalamidino)—1— ethylurea 3-(2-thiazoalamidino)-1-methylurea 3-(4-thxazoalamidino)-1-methylurea . 3—(5-thiazoalamidino)—1— e h lurea

20 3-(1-pyrazoalamidino)-1— ethylurea

3-(1-[3-pyrrolino]amidino)-1-methylurea 3-(2-pyrrolinoamidino)-1-methylurea 3-(1-morpholinoamidino)—1— ethylurea 3—(2-morpholinoamidino)—1-methylurea

25 3-(2-pyrimidinoamidino) -1-methylurea 3-(4-pyrimidinoamidino)—1-methylurea 3-(2-quinolinoamidino)-1-methylurea 3-(4-quinolinoamidino)-1-methylurea

Table I (continued)

3- (2- [5-chloro thiophenyl] amidino) -3-methylurea 3- (2-ρyridyl-N-oxideamidino) -1- (N ^' _/ N-dimethyl) urea

3-(2- 3-cyan.opyχ-idyl]amidino)-1-methylurea

3-{2- 3-carbomethσxypyridyl3amidino)-1-methylurea

3-(2- 3-carboethoxypyridyl]amidino) -1-methylurea

3-(2- 6-chloroρyridyl3amidino)-1-methylurea

3-(2- 6-methyIpyridyl]amidino)-1-methylurea

3-(2- 3-ethyIpyridyl]amidino)-1-methylurea 3-(3- 2-methylpyridyl]amidino)-1-methylurea

3-(3-[2-ethyIpyridyl]amidino)-1- methylurea

3-(3-[2,6-dimethyIpyridyl]amidino)-1-meth lurea

3-(2-[3-cyanothiophenyl]amidino)-1-π.ethylurea

3-(2- [3-carbomethoxythiophenyl3amidino)-1-methylurea

3-(2-[3-carboethoxythiophenyl]amidino)-1-methylurea

3-(3-[2-methoxypyridyl]amidino)-1-methylurea

3-(3-[2-ethoxypyridyl3amidino)-1-methylurea

•3-(3-[2-chloropyridyl]amidino)-1-methylurea

1-(2-furylamidino)urea

1-(3-furylamidino)urea

1-(2-[3-meth If ryl] midino)urea

3-(2-f rylamidino-1- ethylurea

3-(2-furylamidino)-1- propylurea

3-(2-furylamidino)-1- i-propylurea

3-(2-furylamidino)-1- butylurea

3-(2-furylamidino)-1- i-butylurea

3-(2-furylamidino)-1-sec-butylurea .

3-(2-furylamidino)-l---t-butylurea

Table I (continued)

3- 4-pyridylamidino)-l-propargylurea

3- 4-pyridylamidino)-1-allylurea

3- 4-pyridylamidino)-l-methoxyethylurea

3- 4-pyridylaraidino)-1- enzyloxyethylurea

5 3- 4-pyridylamidino)-l-phenethoxyethylurea

3- 4-pyridylamidino)-1- (N,N-dimethyl_urea

3- 4-pyridylamidino)-1-(N,N-diethyl)urea

- 3- 4-pyridylamidino)-1- (N-methyl-N-ethyl) rea

3- 4-pyridylamidino)—1—(N,N-tetramethylene)urea 0 3- 4-pyridylamidino)-1—(N,N-pentamethylene)urea

3- 4-pyridylamidino)-1-(N,N-hexamethylene)urea

3- 4-[2-ethyIpyridyl]amidino)-1-methylurea .

__ 3- 4-[2-ethyIpyridyl]amidino)-1-ethylurea

3- 4-[2-ethyIpyridyl]amxdino)-1-propylurea 5 3- 4—[2-eth Ipyridyl]amidino)—1—butylurea

3- 4-[2—ethyIpyridyl]amidino)—1—i—butylurea

3- 4—[2-eth Ipyridyl]amidino)—1—pen ylurea

3- 4-[2-eth Ipyridyl]amidino)—1— llylurea

3- 4-[2-ethyIpyridyl]amidino)-1— ropargylurea 0 3- 4-[2-ethyIpyridyl]amidino)-1-methoxyethylurea

3- 4-[2-ethyIpyridyl]amidino)-1—benzylox eth lurea

3- 4-[2-ethyIpyridyl]amidino)-1-(N,N-dimethyl)urea

3- 4-[2-ethyIpyridyl]amidino)-1-(N _x N-diethyl)urea

3- 4-[2,6-dichloropyridyl]amidino)-1-methylurea 5 3- 4-[ 1,6-dimethylpyridyl]amidino)-1-mεthylurea

3- 4-[2-methyl,6-chloropyridyl amidino)-1-methylurea

3- 2-thiophenylamidino)-1-methylurea

3- 3-thiophenylaraidino)-1-mεthylurea .

OMPI

3-(3-pyridylamidino)-1-methylurea 3-(3-ρyridylamidino)-1-ethylurea 3-(3-pyridylamidino)-1-propylurea 3-(3-pyridylamidino)-1-propylurea 3-(3-pyridylamxdino-l-butylurea 3-(3-pyridylamidino)-1-i-butylurea

3-(3-pyridylamidino)-1-t-butylurea

3-(3-pyridylamidino)-1-pentylurea

3-(3-pyridylamidino)-1-allylurea 3-(3-pyridylamidino)-1-propargylurea

3-(3-pyridylamidino)-1-cyclobutylurea

3-(3-pyridylamidinσ)-1-cyclohexylurea

3-(3-pyridylamidino)—1-benzylurea 3-(3-pyridylamidxno)-1-methoxyethylurea 3-(3-pyridylamidino)—1-benzyloxyethylurea 3-(3-pyridylamidino)-lrmethoxyethylurea 3-(3-pyridylamidino)-1-benzyloxyethylurea 3-(3-pyridylamidino)-1-phenethoxyethylurea 3-(3-pyridylamidino)-1- (N,N-diethyl)urea 3-(3-pyridylamidiήo)-1- (N,N-dimethyl)urea

3-(3-pyridylamidino)-1-(N,N-pentamethylene)urea 3-(4-pyridylamidino)—1-methylurea 3-(4-pyridylamidino)-1-ethylurea 3-(4-pyridylamidino)-1-propylurea 3- (4-pyridylamidino)-1-i-propylurea 3-(4-pyridylamidino)-1-butylurea 3-(4-pyridylamidino)-1-t-butylurea 3-(4-pyridylamidino)-1-pentylurea

OMPI

Table I (continued)

3- (2-[ [3-methyIpyridyl]amidino -1-phenethoxyethylurea

3- (2-[[3-methylpyridyl]amidino -1-benzylurea

3- (2-[[3-methylpyridyl]amidino -1-(N,N-dimethy1)urea

3- (2-[[3-methylpyridyl] midino -1- (N _/ N-diethyl)urea

3- -(2-[ [3-methyIpyridyl]amidino -1-(N Nrtetramethylene)urea

3- -(2-[ [3-methyIpyridyl] midino -1-(N _/ N-pentamethyleneJurea

3- -(2-[ [3—chloropyridyl]amidino -1-methylurεa

3- •(2-[ [3—chloropyridyl]amidino -1—ethylurea

3- -(2-[ [3—chloropyridyl] midino -1— ropylurea

3- -(2-[ [3—chloropyridyl]amidino -1-i-proρylurea

3- (2-[ [3-chloropyridyl]amidino -1-butylurea

3- (2-[ [3—chloropyridyl]amidino -1-i-butylurea

3- (2-[ [3—chloropyridyl]amidino -1-t-butylurea

3- (2-[ [3-chloropyridyl]amidino -1— entylurea

3- (2-[ [3—chloropyridyl]amidino -1-allylurea

3- (2-[ [3-chloropyridyl]amidino -1-propargylurea

3- (2-[ [3-chloropyridyl]amidino -1-cyclopropylurea

3- ^• (2-1 [.3—chloropyrxdyl]amidino -1-cyclobutylurea

3- -( ^[[3—chloropyrxdyl]amidino -1-cyclopropylmethylurea

3- -(2-[ [3-chloropyrxdyl]amidino -1-methoxyethylurea

3- 2-[ [3—chloropyridyl]amidino -1-benzylox ethylurea

3- - C2-[ [3—chloropyridyl]amidino -1-phenethoxyeth lurea

3- (2-1 I3-chloropyrxdyl]am dino -1-bεnzylurea

3- (2-[ [3-chloropyridyl]amidino -1-(N,N-dimethyl) rea

Table I (continued)

3-(2-pyridylamidino)-1-methylurea

3-(2-pyridylamidino)-1-ethylurea

3- (2-pyϊridylamidino) -1-propylurea

3-(2-pyridylamidino)-1-i-propylurea 3-(2-pyridylamidino)-1-butylurea

3- ^" (2-pyridylamidino)-1-i-butylurea

3-(2-pyridylamidino)-1-pentylurea

3-(2-pyridylamidino)-1-propargylurea

3-(2-pyridylamidino)-1-allylurea 3-(2-pyridylamidino)-1-methoxyethylurea

3-(2-pyridylamidino)-1-benzyloxyethylurea

3-(2-pyridylamidino)-1-phenethoxyethylurea 3-(2-pyridylamidino)-1-(N,N-dimethyl)urea 3-(2-pyridylamidino)-1-(N,N-diethyl)urea 3-(2-pyridylamidino)-l-(N,N-tetramethylene)urea 3-(2-pyridylamidino)—1-(N,N-ρentamethylene)urea 3-(2-pyridylamidino)-1-(N_.N-hexamethylene)urea 3-(2-[3-me hyIpyridyl]amidino)-1-methylurea 3-(2— ^" [3-methylpyridyl]amidino)-1-ethylurea 3-(2-[3-methylpyridyl]amidino) -1-propylurea

3-(2-[3-me h lpryidyl]amidino)-1-i-prbpylurea 3-(2-[3-me hylpyridyl]amidino)-1-i-butylurea 3-(2-[3-methyIpyridyl]amidino) -1-pentylurea 3-(2- [3-methylpyridyl3amidino)-1-allylurea 3- (2-[3-methylpyridyl3amidino) -1-propargylurea

3- (2-[3-methyIpyridyl]amidino)-1-cyclopropylurea 3-(2-[3-methylpryidyl]amidino)-1-methoxyethylurea

OMPI

Table I (continued) l-(2 '-pyridylmethyl) -3-methylamidinourea l-(2 *-pyridylmethyl)-3-ethylamidinourea l-(2 '-pryidylmethyl)-3-propylamidinourea l-(2 *-pyridylmethyl)-3-i-propylamidinourea l-(2'"Pyridylmethyl)-3-butylamidinourea l-(2 *-pyridylmethyl)-3-i-butylamidinourea l-(2'-pyridylmethyl)-3-pentylamidinourea l-(2 ¹ -pyridylmethyl)-3-propargylamidinourea l-(2 "-pyridylmethyl)-3-allylamidinourea l-(2 '-pyridylmethyl)-3-methoxyethylamidinourea l-(2 *-pyridylmethyl)-3-benzyloxyethylamidinourea l-(2 '-pyridylmethyl)-3-phenethoxyethylamidinourea l-(2'-pyridylmethyl) -3- (N _/ N-dimethylamidino)urea l-(2'-pyridyl thyl) -3- (N,N-diethylamidino)urea l-(2 *-pyridylmethyl)-3—(N N-tetramethyleneamidino)urea l-(2'"Pyridylmethyl)-3- (N _/ N-pentamethyleneamidino)urea l-(2'"Pyridylmethyl)-3-(N,N-hexamethyleneamidino)urea l-(3 ¹ -methyl-2'-pyridylmethyl)-3-methylamidinourea l-(3 *-methyl-2'-pyridylmethyl)-3-ethylamidinourea l-(3'-methyl-2'-pyridylmethyl)-3-propylamidinourea l-(3 ^f -methyl-2'-pyridylmethyl)-3-i-propylamidinourea l-(3'-methyl-2'-pyridylmethyl) -3-i-b tylamidinourea l-(3'-methyl-2 ¹ -pyridylmethyl)-3-ρentylamidinourea l-(3'-methyl-2'-pyridylmethyl)-3-allylamidinourea l-(3 '-methyl-2'-pyridylir.--.thyl)-3-ρropargylaπι5.dinourea l-(3'-methyl-2*-pyridylrriethyl)-3-cyclopropylamidir.ourea l-(3'-methyl-2*-pyrjdylnethyl)-3-m Lhoκyethylamidinourea l-(3'-πethyl-2'-pyridylmethyl)-3-benzyloxyet yla_rilirιθ'

OMPI

Tabl-e ³⁹ I ^_ (contxnued)

1-(3'-pyrxdylmethyl)-3-t-butylamidinourea 1-(3*-pyridylmethyl)-3-pentylamidinourea 1-(3*-pyridylme hyl)-3-allylamidinourea 1-(3'-pyridylmethyl)-3-propargylamidinourea l-(3'-pyridylmethyl) -3-cyclobutylamidinourea 1-(3'-pyridylmethyl)-3-cyclohexylamidinourea 1-(3*-pyridylmethyl) -3-benzylamidinourea 1-(3'-pyridylmethyl) -3-methoxyethylamidinourea 1-(3'-pyridylmethyl)-3-benzyloxyethylamidinourea 1-(3'-pyridylmethyl)-3-methoxyethylamidinourea 1-(3'-pyridylmethyl)-3-benzyloxyethylamidinourea 1-(3'-pyridylmethyl) -3-phenethoxyethylamidinourea 1-(3'-pyridylmethyl)-3-(N,N-dimethylamidino) urea 1-(3'-pyridylmethyl)-3-(N,N-diethylamidino)urea

1-(3'-pyridylme hyl)-3-(N,N-pentamethyleneamidino)urea 1-( '-pyridylmethyl) -3-methylamidinourea

1-(4'-pyridylmethyl) -3-ethylamidinourea l-(4'-pyridylmethyl)-3-propylamidinourea 1-(4'-pyridylme hyl)-3-i-propylamidinourea l-(4'-pyridylmethyl)-3-butylamidinourea

1-(4'-pyridylmethyl)-3- t-butylamidinourea

1-(4'-pyridylmethyl)-3-pentylamidinourea

1-(4'-pyridylme hyl) -3-hexylamidinoui'ea 1-(4'-pyridylmethyl)-3-propargylamidinourea

1-(4'-pyridylmethyl)-3-allylamidinourea

1-(4*-pyridylmethyl)-3-methoxyethylami inourea l-(4'-pyridylmethyl)-3-benzyloxyethylami inourea l-(4'-pyridylmethyl)-3-phfπethcκyethylami inourea

Table I (continued)

1- ₍ 4'-pyridylmethyl)-3-(N,N-tetramethyleneamidino)urea 1_(4•-pyridylmethyl)-3- ^~ (N,N-pentamethyleneamidino)urea 1-(4*-pyridylmethyl)-3-(N _/ N-hexamethyleneamidino)urea 1- ₍ 2*-ethyl-4'-pyridylmethyl)-3-methylamidinourea 1-(2*-ethyl-4'-pyridylmethyl)-3-ethylamidinourea 1_(2'-ethyl-4'-pyridylmethyl)-3-propylamidinourea 1-(2*-ethyl-4'-pyridylmethyl) -3-butylamidinourea 1-(2'-ethyl-4'-pyridylmethyl)-3-i-butylamidinourea 1-(2*-ethyl-4'-pyridylmethyl)-3-pentylamidinourea 1_(2'-ethyl-4' -pyridylmethyl)-3-allylamidinourea 1_(2*-ethyl-4'-pyridylmethyl)-3-propargylamidinourea 1_ ₍ 2'-ethyl-4'-pyridylmethyl) -3-methoxyethylamidinourea 1_ ₍ 2'-ethyl-4'-pyridylmethyl)-3-benzyloxyethylamidino rea 1-(2'-ethyl-4'-pyridylmethyl)-3-(N,N-dimethylamidino)urea l- ₍ 2 ^f -ethyl-4*-pyridylmethyl)-3-(N,N-diethylamidino) i--ea

1-(2' ,6*-dichloro-4'-pyridylmethyl)-3-methylamidinourea l-(2' ,6'-dimethy1-4'-pyridylmethyl) -3-methylamidinourea l-(2'-thiophenylmethyl)-3-methylamidinourea l- ⁽ 3'-thiophenylmethyl)-3-methylamidinoύrea

1-(5 ^* -methy1-2'-thiophenylmethyl)-3-methylamidinourea 1-(5'-chloro-2*-thiophenyl ethyl)-3-methylamidinourea l- ⁽ 2'-pyridylmethyl-N-oxide)-3- (N,N-dimethylamidino)urea 1-(3*-cyano-2'-pyridylmethyl)-3-methylamidinourea l-(3 ^* -carbomethoxy-2'-pyridylιπethyl-3-methylamidinourea l-(3'-carboethoxy-2'-pyridyl.τ.e hyl) -3- ethylamidinourea l-(6 ^, -chloro-2'-pyridylmethyl)-3- methylamidinourea 1-(6 ^, -m. hyl-2 ^r -pyridylr..et<ιyl) -3-methylamidinourea

1-(3*-ethy1-2'-pyri ylmethyl) -3- methylamidinourea

Table I (continued) l-(l'-imidazolylmethyl)-3-methylamidinourea l-(2'-imidazolylmethyl) -3-methylamidinourea 1- (4 '-imidazolyl e hyl) -3-methylamidinourea l-(2'-oxazolylmethyl) -3-methylamidinourea l-H'-oxazolylmethyl) -3-methylamidinourea 1- (5'-oxazolylme hyl) -3-methylamidinourea l-(2'-thxazolylmethyl) -3-methylamxdinourea 1- (4'-thiazolylmethyl) -3-methylamidinourea l-(5'-thiazOlylmethyl)-3-methylamidinourea

1- (l'-pyrazolylmethvl) — 3-methvlamidinourea 1- (3 '-pyrrolidinylmethyl) -3-methylamidinourea 1- (2 ' -pyrrolidinylmethyl) -3-methylamidinourea 1- (4 * -morpholinylme hyl) -3-methylamidinourea 1- (2 '-morpholinylmethyl) -3 -methylamidinourea l-(2'-pyrimidinylmethyl) -3-methylamidinourea

1- (4 '-pyrimidinylmethyl) -3 -methylamidinourea l-(2'-quinolylmethyl) -3-methylamidinourea l-(4 '-quinolylmethyl) -3-methylamidinourea l-(l ^, -isoquinolylmethyl) _. -r-3-methylamidinourea l-(furfuryl-3-cyclopeny lamidinourea

1- (furfuryl-3-cyclohexyl amidinourea

1- (f urf uryl-3-phenylamidinourea

1- (f urf uryl-3-benzylamidinourea 1- (f urfuryl-3-phenethylamidinourea

l-furfuryl-3- (N-methyl-N-benzylamidino) urea l-fυrfuryl-3-(N _/ N-dibenzylamidino) urea 1- "tetrahydrof rf uryl-3-amidinourea

OMPI

Table I (continued)

1- (4 * -imidazolylmethyl ) -3-amidinourea

1- (1* -methyl-4 * -imidazolylmethyl) -3-amidinourea

1- (2 ' -methyl-4 ' -imidazolylmethyl) -3-amidinourea 1- (2* -imidazolylmethyl) -3-amidinourea l-(2'-oxazolylmethyl) -3-amidinourea 1- (4 ' -methyl-2 ' -oxazolyl ethyl) -3-amidinourea 1- (4 * -oxazolylmethyl) -3 -amid inourea 1- ( ' -methyl-2 * -oxazolylmethyl) -3-amidinourea 1- (4 * -oxazolylmethyl) -3-amidinourea

1- (2* -methyl-4' -oxazolylmethyl) -3-amidinourea 1- (5' -oxazolylmethyl) -3 -amidinourea l-(2' -methyl-5' -oxazolylmethyl) -3-amidinourea l-(4 '-thiazolylmethyl) -3-amidinourea l-( 5* -methyl-4' -thiazolylmethyl) -3-arnidinourea 1- (5 '-thiazolylmethyl) — 3-amidinourea 1- (4 * -methyl-5 * -thiazolylmethyl) -3-amidinourea 1- (1* -pyrazolylmethyl) -3-amidinourea l-(3'-pyrrolylmethyl) -3-amid inourea 1- (2 -me thy 1-3 ' -pyrrolyl e hyl) -3 -amid inourea 1- ( -methyl-2' -pyrrolylme hy 1) -3-amidinourea 1-(1* -pyrrolidinylmethyl) — 3-amidinourea 1- (2 ' -methyl-1 '-pyrrolidinylmethyl) -3-ami inourea 1- (11 -methyl-2 ' -pyrrolidinylmethyl) -3 -amidinourea 1- (4 '-morpholinylmethyl) — 3-amidinourea

1- (2 '-methyl-4 '-morpholinylmethyl) -3 -ami inourea 1- (2* -morpholinylmethyl) — 3-aιnidinourea 1- (4 '-ϊ.ie thy 1-2 '-morpholinylmethyl) -3 -amid 5 ourea 1- (3 ' -methyl-2 ' - orphol i nylir.ethyl) -3-amid i nourea

Table I (continued) _ [ 2 - ( 2 * -py ridy D thyl ) -3-methy lamidinourea 1- [2 -(2 '-pyridyl) ethyl] -3-ethylamidinourea 1_[ 2- (2* -pry dyl) ethyl] -3-propylamidinourea 1- [2- (2 '-pyridyl) ethyl] -3-i-propy lamidinourea 1- 12- (2* -pyridyl) ethyl] -3-bu tylamidinourea 1- [2- (2 '-pyridyl) e thy 13 -3-i-bu tylamidinourea 1- [2- (2 '-pyridyl) ethyl] -3-pe tylamidinourea 1- [2- (2* -pyridyl) ethyl] -3-propargylamidinourea 1- [2- (2* -pyridyl) ethyl] -3-allylamidinourea

1- [2- (2 '-pyridyl) ethyl3 -3-methoxyethylamidinourea l-[2- (2 '-pyridyl) ethyl3 — 3-benzyloxyethylamidinourea 1- [2- (2 '-pyridyl) ethyl3 -3-phenethoxyethylamidinourea l-[ 2- (2' -pyridyl) ethyl] -3- (N/N-dimethylamidino) urea l-[2- (2* -pyridyl) ethyl3 -3- (N _/ N-diethylarnidino) urea

1- [2- (2 '-pyridyl) ethyl] -3- (N _/ N-tetramethylenearnidinόJ rea l-[2-(2*-pyridyl).ethyl3 -3- (N^-pentamethylenearnicinoJ ⁱⁱ rea l-[2-(2'-pyridyl).ethyl3 -3- (N,N-hexamethylene amidino) urea 1- [2- (3' -me thy 1-2' -pyridyl) ethyl) -3-methylamidinourea l-[2- (3« -me hy 1-2 '-pyridyl) ethyl] -3-ethylamidinourea l-[2- (3 '-me thy 1-2':- pyridyl) ethyl] -3-propylaπιidinourea l-[ - (3 '-methyl-2 '-pyridyl) ethyl] -3-i-propylamidinourea 1- [2- (3 '-methyl-2 '-pyridyl) ethyl) -3-i-bu tylamidinourea 1- [2- (3' -methyl-2' -pyridyl) ethylj -3-ρcntyla idinourea 1- [2- (3 '-methyl-2 '-pyridyl) .ethyl] -3-ally ^] mi inourea

1- [2- (3* -methyl-2 '-pyridyl) ethyl] -3-ρropargy lamidinourea

OMPI

1-[2-(3*-pyridyl) ethyl ^' 3 -3-t-butylamidinourea 1-[2-(3*-pyridyl).ethyl] -3-pentylamidinourea 1-[2-(3"-pyridyl) ethyl] -3-allylamidinourea 1-[2-(3 *-pyridyl) ethyl] -3-propargylamidinourea 1-[2-(3'-pyridyl) ethyl] -3-cyclob tylamidinourea 1-[2-(3'-pyridyl).ethyl] -3-cyclohexylamidinourea 1-[2-(3*-pyridyl).ethyl] -3-benzylamidinourea 1-[2-(3'-pyridyl) ethyl]-3-methoxyethylamidinourea l-[ 2-(3'-pyridyl).ethyl]-3-benzyloxyethylamidinourea l-[2-(3'-pyridyl).ethyl]-3-methoxyethylamidxnourea 1-12-(3'-pyridyl) ethyl]-3-benzyloxyethylamidinourea 1-[2—(3'-pyridyl) ethyl! -3-phenethoxyethylamidinourea 1-12-(3*-pyridyl) ethyl] -3-(N N-dimethylamidino)urea 1-[2-(3*-pyridyl) εthyl -3-(N,N-diethylamidino)urea 1-[2-( '-pyridyl) ethyl3-3- ethylamidinourea

1-[2-(4'-pyridyl) ethyl]-3- _e thylamidinourea l-[2—(4'—pyridyl) ethyl]—3-propylamidinourea l-[2—( '—pyridyl) ethyl] -3—i-propylamidinourea 1-[2-(4'-pyridyl) ethyl] -3-butylamidinourea 1-[2-(4'-pyridyl) ethyl] -3-.t-butylamidinourea 1-[2—( '-pyridyl) ethyl]-3-pentylamidinourea l-[2—(4'—pyridyl) fthyl)-3—hexylamidinourea 1-[2-(4*-pyridyl) ethyl)-3-propargylamidinourea 1-[2-(4*-pyridyl) ethyl3-3-allylamidinourea l-[2-(4'-pyridyl) ethyl3-3-methoxyethyla_rιidir_ourea 1-[2-(4*-pyridyl) ethyl)-3-benzyloxyethylami inourea l-[2-( '-pyridyl) ethy13-3-phenethoκ ethyl m inourea

Table I (continued)

1- [3- (2 '-pyridyl) propyl] -3 -methylamidinourea 1- [3- (2 '-pyridyl) propyl] -3-ethylamid inourea 1- [3- (2 ' -pyridyl) propyl] -3 -propy lamidinourea 1- [3- (2 ' -pyridyl) propyl] -3-i-propylamidinourea l-[3- (2" -pyridyl) propyl] -3-butylamidinourea l-[3- (2 '-pyridyl) propyl] -3-i-bu tylamidinourea l-[3- (2 '-pyridyl) propyl) -3-pentylamidinourea 1- [3- (2 '-pyridyl) propyl] -3-propargylamidinourea l-[3- (2 '-pyridyl) propyl] -3-allylamidinourea

1- [3- (2 ' -pyridyl propyl] --3-methoxyethylamidinourea l--[3τ--(.2 '-pyridyl Ipropyl] -3-benzyloxyethylamidinourea l-[3- (2 ' ^• t- pyr idyl) ^" propy 1J ^3^-phenethoxyethylamidinourea l-r-13- ( _. 2 ' -pyridyl ipropyl] _^ -3- (N,N^di_me thy lamidino urea 1-13^- (2*-pyridyl).propyl]-3- (N,N-diethylamidino")urea

1- [3- (2 '-pyridyl) propyl] -3- (N _# N-tetramethyleneamidino)urea l-[3- (2 '-pyridyl) propyl] -3- (N,N-pentamethylenεamidino)urea l-[3- (2 '-pyridyl) propyl] -3- (N _/ N-hexamethyleneamidino)ur3a l-[3- (3 '-methyl-2 '—pyridyl) propyl] -3 -methylamidinourea l-[3- (3 'methyl-2 * -pyridyl) propyl] -3-ethylamidinourea

1- [3- (3 * -methyl-2 ' -pyridyl) propyl] -3-propylamidinourea 1- [3- (3 * -methyl-2 * -pyridyl) propyl] -3 -i-r-propyl amid inourea l-[3-(3 '-methyl-2 * -pyridyl) propyl] -3-i-butylami'd inourea 1- [3- (3 * -methyl-2 ' -pyridyl) ropyl] -3-penty lamidinourea l-[3- (3 '-methyl-2* -pyridyl) propyl] -3-allylamidinourea 1- [3- (3 ' -methyl-2 * -pyridyl) propyl] -3-propargylamidino

OMPI

Table I (continued) l-[3-(3* - pryidyl) propyl] -3- -bu ylamidinourea l-[3-(3' - pyridyl) propyl] -3 -pen tylamidinourea l-[3-(3' - pyridyl) propyl] -3-allylamidinourea

5 l-[3-(3* -pyridyl) propyl] -3-propargylamidinourea l-[3-(3* -pyridyl) ropyl] -3-cyclobutylamidinourea l-[3-(3' - yridyl)-proρyl] -3-cyclohexylamidinourea l-[3-(3' -pyridyl) propyl] — 3-benzylamidinourea l-[3-(3 ^t -pyridyl) propyl] -3-methoxyethylamidinourea

10 l-[3-(3* --pyridyl} propyl] -3-benzyloxyethylamidinourea l-[3 -(3' -pyridyl) propyl] -3-methcxyethylamidinourea l-[3-(3* -pyridyl) propyl]- -3-benzyloxyethylamidinourea l-[3-(3' -pyridyl). propyl) -3-phenethoxyεthylamidinourεa l-[3-(3' -pyridyl) propyl]■ ^' -3- (N,N-dime hy lamidino) rea

15. l-[3-(3' -pyridyl) propyl] -3- (N,N-die thy lamidino) urea l-[3-(3' -pyridyl ₎ propyl) -3- (N,N-pεntamεthyleneamidir_c) rea l-[3-_(4* -pyridyl) propyl) -3- ethylamidinourea l-[3-(4* -pyridyl) propy If -3- e thy lamidinourea l-[3-(4* -pyridyl) _. propyl] -3- propylamid inourea 0 l-[3-(4' —pyridyl). propy 13 -3— i— propy lamidinourea l-[3-(4 ^« -pyridyl) .propy 1] -3- bu tylamidinourea l-[3-(4 ^» -pyridyl) propyl] -3- t-butylamidinourea l-[3-(4* -pyridyl) propy ϋ -3-pentylamidinourea l-[3-(4 ^« -pyridyl). propyl] -3- hexy lamidinourea

25 l-[3-(4* -pyridyl) propyl]_--3- propargylair.idinourea l-[3-(4* -pyridyl) _. propyl] -3- allylαmi inourea l-[3-(4* -pyridyl) _. propyl) -3- methoxye hy lamidinourea l-[3-(4* -pyridyl). ropyl] -3-benzy oxyethylamidinourea l-[3-(4* -pyridyl) propyl] -__- phcnethoxy thyl amidinourea

Table I (continued) l-[3-{3'-ρryidyl)proρyl3 -3- -buty lamidinourea

1- 13 - (3 ' - pyridyl) propyl] -3-pentylamidinourea

1- [3 - (3 ' - pyridyl) propyl) -3-allylamidinourea 1- [3- (3 '-pyridyl) propyl] -3-propargylamidinourea

1- [3 - (3 * - -pyridyl) propyl] -3-cyclobu ylamidinourea

1- [3 - (3 * -pyridyl) propyl] -3-cyclohexylamidinourea

1- [3 - (3 ' -pyridyl) propyl] — 3-benzylamidinourea

1- [3 -(3 '-pyridyl) propyl) -3-methoxyethylamidinourea l-[3 - (3' --pyridyl) propyl) -3-benzyloxyethylamidinourea l-[3 - (3'- ^r i ^< 3y ) propyl] -3-methoxyethylamidinourea l-[3 - (3 '-pyridyl) propy -U; -3-benzyloxyethylamidinourea

1- [3 - (3 * -pyridyl). propyl] -3-phenethoxy ethylamidinourea l-[3-(3'-Pyridyl) propy J.-S-tN N-dimethylamidinoJurεa 1- [3 -(3 '- yri^yD propy U -3- (N,N-diεthylamidino)urea 1- [3 - (4 * -pyridyl) propyl] -3- methylamidinourea l-[3 - (4* -pyridyl) propy 1J. -3- ethylamidinourea

1- [3 -(4 '-pyridyl). propyl] -3-propylamidinourea " . • '•

1- [3 - (4 ' -pyriάyl)_proρyl) -3- i-propylamidinourea l-[3 -(4'-Eyri ^' <3yl).proρy_l] -3-butylamidinourea l-[3 -(4 '-pyridyl) propyU -3- t-butylamidinourea l-[3 - (4 '-pyridyl) propy U -3- pen tylamidinourea 1- [3 - (4 '-pyridyl). propy ] -3-hexylamidinourea l-[3 - (4* -ρyrii-dyl).propyl];. _^ -3-propargylamid inourea l-[3 -(4' -pyx-idyl). propyl) -3- llylamidinourea l-[3 -(4 '-pyridyl) propyl] -3- ir.ethoxy ethylamidinourea l-[3 - (4 '-pyridyl) propyl] -3-benzyloxyethylamidinourea l-[3 -(4* -pyridyl) propyl! -3- phene t oxye thy lami d inourea 1- [3 - (4 ' -i^ricyl) ro yl] -3- (_ϊ, -di_r.c- thy] amidino) urea

Table I (continued) 1-(2'-methyl-3'-morpholinylmethyl)-3-amidinourea

1_(2»-pyrimidinylmethyl)-3-amidinourea

1- ₍ 4'-methyl-2'-pyrimidinylmethyl)-3-amidinourea 1-(4'-pyrimidinylmethyl)-3-amidinourea

1-(2'-methyl-4'-pyrimi inylmethyl) -3-amidinourea l-(2 ^, -quinolylmethyl)-3-amidinourea

1- ₍ 3'-methyl-2'-quinolylmethyl) -3 _^ -amidinourea 1 _^ (4'-quinolylmethyl). _^ -3 _^ -amidinourea

1-(3*-meth l-4*-quinolylmethyl) -3-amidinourea 1-(I'-isoquinolylmethyl) _. -3 - amidinourea 1-(3*-morpholinylmethyl)-3-amidinourea 1-(4*-methyl-3'-morpholinylmethyl)-3-amidinourea 1-(3'-mεthyltetrahydrofurfuryl)-3-amidinourεa 1-(1'-imidazolylmεthyl)-3-amidinourea 1-(2'-methyl-1'-imidazolylmethyl)-3-amidinourea l-[2-(3'-pyridyl)ethyl]-3-(N _/ N-pentamethyleneamidino)urea 1-[2-(4'-pyridyl)ethyl]-3-(N/N-dime hylamidino)urea 1-[2-(4'-pyridyl)ethyl]-3-(N,N-diethylaπ_idino)urea 1-[2-(4'-pyridyl)ethyl]-3-(N-methy1-N-ethylamidino)urea 1-[2-(3'-methyl-2'-pyridyl)ethyl]-3-(N,N-tetramethylene- amidino)urea 1-[2-(3'-methyl-2'-pyridyl)ethyl]-3-(N,N-pεntamethylene- amidino)urea 1-(2'-methy1-3*-pyridylmethyl)-3-(methylamidino)urea 1-(2'-ethyl-3'-pyridylmethyl)-3-(methylamidino)urea

1-(2' ,6'-dimethy1-3'-pyridylmethyl)-3-(methylamidino)urea

1-(3*-cyano-2 ^, -thiophenylmethyl)-3-(methylamidino)urea

1-(3'-carbomethoxy-2'-thiophenylmethyl)-3-(methylamidino) -

Table I (continued) urea 1- (3 ' -carboethoxy-2 ' -thiophenylmethyl) _. -3- (methylamidino) - urea 1- (2 ' -me hoxy-3 ' -pyridylmethyl) -3- (methylamidino) urea 1- (2 * -ethoxy-3 ' -pyridylmethyl) -3- (methylamidino) urea 1- (2 ^* -chloro-3 ^• -pyridylmethyl) -3- (methylamidino) rea l-furfuryl-3-amidinourea 1- (3 ' -methyl-f urf uryl) -3-amidinourea l-furfuryl-3-ethyl amid inourea ι_f _ur f _ur yi_3-propylamidinourea

1-f urf uryl-3-x-propy lamidinourea l_f _ur f _ur yl_3_bu tylamidinourea l_f _ur f _ur yl_3-i-butyl amidinourea

l-furfuryl-3- ^sec ~ ^t,ut yl ^am - ^{id :i} - ^nourea 1-f urf ry 1-3- t-butyl amidinourεa l_f _ur f _ur yl_3_ entylamidinourea l-furfuryl-3- hexylamidinourea 1-f urfury 1-3 -hεptylamidinourea l-fu furyl-3- ^c y ^c l ⁰ P ^rσ Py ^larn - ^id*inourea ₁ _ _furfury ι_3_cycloouty lamidinourea

l- (2 ' -pyridylmethyl-N-oxide) -3-methylami.d 1- (3 ' -pyridylmethyl-N-oxide) -3-methylamidinourea 1- (4 ' -pyridylπethyl-N-oxide). _" 3-me thylαmid inourea l-fυrfυryl-3- .-ιethyl am dinourea

1- tetrahydrof urf uryl- 3-me thylamidinourea

Table I (continued)

1-0-I2- 3 ' -chloro-2 • -pyridyl) eth 33 -3-methylamidinourea -

1-12- 3*-chloro-2 « -pyridyl) ethyl] -3-ethylamidinourea

1-12- 3*-chloro-2 i -pyridyl) ethyl] -3-propylamidinourea

1-12- 3*-chloro-2 • -pyridyl) thyl] -3-i-propylamidinourεa

1-12- 3 ' -chloro-2 '-pyridyl) εthyl] -3-bu tylamidinourea 1-12- 3 ' -chloro-2 • -pyridyl) -ethyl] -3-i-bu ylamidinourea 1-12. 3'-chloro-2 ^« -pyridyl) ethyl] -3-t-butylamidinourea 1-12- 3 ' -chloro-2 ^» -pyridyl) εthyl] -3-pentylamidinourea 1-12 - 3 ' -chloro-2 '-pyridyl) ethyl] -3-allylamidinourea 1-12. 3 '-chloro-2' -pyridyl) ethyD -3~propargyla:nidinoure l-[2- 2 '-pyridyl )ethyl]-3-methylamidinourea l-[2- 2 '-pyridyl) ethyl ]-3-ethylaτr .idinourea l-[2- 2 '-pyridyl ⁾ ethyl 3 -3-propy lamidinourea l-[2- 2 '-pyr yl ⁾ ethyl 1-3-i-propy lami inourea l-[2- 2 '-pyridyl) ethyl ]-3-b ylamidinourea l-[2- 2 '-pyridyl) ethyl ^] -3-i-butyla:nidir_ourca l-(4' -pyridylmethyl) -3- (N ,N-dime thy lamidino) urea l-(4' -pyridylmethyl) -3- (N,N-diet_hylamidino) urea l-(4' -pyridylmethyl) -3- (N-methyl-N-ethy lamidino) urea l-[2- (3 ' -methyl-2 ' -pyridyl) ethyl] -3-cyclopropylamidinourea l-[2- (3 ' -methyl-2 ' -pyridyl) ethyl] -3 -me hoxye hy lamidino¬ urea

1-[2-(3'-methyl-2'-pyridyl)ethyl]-3-benzyloxyethylamidino - urea

1-[2-(3'-methyl-2'-pyridyl)ethyl]-3-phenethoxyethylamidin o¬ urea

1-[2-(3'-methyl-2'-pyridyl)ethyl]-3-benzylamidinourεa

Table I (continued)

1-[2-(3*-methyl-2'-pyridyl)ethyl]-3-(N,N-dimethylamidino) - urea 1-[2- (3'-methyl)2 ^• -pyridyl)ethyl]-3-(N,N-diethylamidino)- urea

1-(3'-methyl-2'-pyridylmethyl)-3-phenethoxyethylamidino)- urea 1-(3'-methyl-2*-pyridylmethyl)-3-benzylamidinourea 1-(3'-methyl-2'-pyridylmethyl)-3- (N,N-dime hylamidino) rea 1-(3'-methyl-2'-pyridylmethyl)-3-(N^N-diethyl m dino) rea 1-(3'-methyl-2'-pyridylmethyl)-3-(N,N-tetramethylene- amidino)urea 1-(3'-methyl-2'-pyridylmethyl)-3-( ,N-pentamethylene- amidino)urea 1-(2'-methyl,6'-chloro-4'-pyridylmethyl)-3-methylamidino¬ urea 1-(3'-chloro-2'-pyridylmethyl)-3-(N-J3'-cyclopentenyl]- amidino)urea 1-(3'-chloro-2'-pyridylmethyl)-3-cyclopropylmethylamidino- urea

1-(3'-chloro-2'-pyridylmethyl)-3-methoxyethylamidinourea 1-(3'-chloro-2'-pyridylmethyl)-3-benzyloxyethylamidinourea 1-(3'-chloro-2'-pyridylmethyl)-3-phenethoxyethylamidinourea 1-(3'-chloro-2*-pyridylmethyl)-3-benzylamidinourea 1-(3'-chloro-2 ¹ -pyridylmethyl)-3-(N,N-dimethylamidino)urea 1-(3'-chloro-2'-pyridylmethyl)-3-( /N-diethylamidino)urea 1-(3'-chloro-2'-pyridylmethyl)-3-(N,N-tetramethylene- amidino)urea

Tahle I (continued)

1_(2'-pyridylmethyl)-3-(N,N[3'-methyl-3'-azapenta ethylene]- amidino)urea 1-(2'-pyridylmethy1-3-(N ,N[3'-oxapentamethylene]amidino)- urea

1-(2'-ethyl-4'-pyridylmethyl)-3-(N,N-tetramethyleneamid_ o)- urea

1-(3*-chloro-2*-pyridylmethyl)-3-methylamidinourea l-(3'-chloro-2'-pyridylmethyl)-3-ethylamidinourea 1- (3 ^* -chloro-2'-pyridylmethyl}-3-proρylamidinourea

1-(3'-chloro-2 ¹ -pyridylmethyl)-3-i-propylamidinourea 1-(3'-chloro-2'-pyridylmεthyl)-3-butylamidinourεa 1-(3'-chloro-2*-pyridylmεthyl)-3-i-butylamidinourεa 1-(3*-chloro-2*-pyridylmεthyl)-3-t-bu ylamidinourea 1-(3'-chloro-2'-pyridylmethyl)-3-pentylamidinourea 1-(3'-chloro-2'-pyridylmethyl)-3- _a llylamidinourea 1-(3'-chloro-2'-pyridylmethyl)-3-propargylamidinourea

1- ⁽ 3 ^* -chloro-2'-pyridylmethyl)-3-cyclopropylamidinourea 1-(3*-chloro-2'-pyridylmethyl)-3- _C yclobutylamidinourea 1-(3*-pyridylmethyl)-3-methylamidinourea 1-(3'-pyridylmethyl)-3-ethylamidinourea 1-(3'-pyridylmethyl)-3-propylamidinourea 1-(3*-pyridylmethyl)-3-i-propy amidinourea 1-(3'-pyridylmethyl)-3-butylamidinourea 1-(3*-pyridylmethyl)-3-i-butylami inourea

Table I (continued)

1-[2-(3'-chloro-2'-pyridyl)ethyl)-3-cyclopropylamidinoure a

1-[2-(3'-chloro-2 ^** -pyridyl)ethyl]-3-cyclobutylamidinourea

1-[2-(3 ^• -chloro-2'-pyridyl)ethyl]-3-(N-] 3'-cyclopentenyl]- amidino) rea

1-[2-(3'-chloro-2'-pyridyl)ethyl]-3-cyclopropyImethyl- amidinourea

1-[2-(3'-chloro-2'-pyridyl)ethyl]-3-methoxyethylamidinour ea

1-[2-(3'-chloro-2'-pyridyl)ethyl]-3-benzyloxyethylamidino - urea

1-[2-(3'-chloro-2'-pyridyl)ethyl)-3-phenethoxyethylamidin o- urea

1- [2-(3'-chloro-2'-pyridyl)ethyl]-3-benzylamidinourea

1-[2-(3'-chloro-2 ^• -pyridyl) thyl]-3- (N,N-dimethylamidino)- urea

1-[2-(3'-chloro-2'-pyridyl)ethyl]-3- (N.N-dimethylamidino)- urea

1-[2-(3'-chloro-2'-pyridyl)ethyl)-3-(N,N~diethylamidino)- urea l-[2-(3*-chloro-2'-pyridyl)ethyl]-3-(N _/ N-tetramethylene- amidino)urεa

1-[2-(2'-pyridyl) thyl]-3-(N,N[3'-methyl-3'-azapenta- methylene]amidino)urea

1-[2-(2'-pyridyl)ethyl]-3- (N, [3'-oxapentamethylene]- amidino)urea -[3-(3'-methyl-2*-pyridyl)propyl]-3-cyclopropylamidinourea -[3-(3'-methyl-2'-pyridyl)propyl]-3-methoxyethylamidino- urea -[3-(3'-methyl-2*-pyridyl)propyl]-3-benzyloxyethylamidino- _^ urea -[3-(3'-methyl-2'-pyridyl)propyl]-3-phenethoxyethylamidino- urea -[3-(3'-methyl-2'-pyridyl) _. propyl]-3-benzylamidinourεa -[3-(3'-methyl-2'-pyridyl)propyl]-3- ( ,N-dimethylamidino)- urea -[3-(3'-methyl-2*-pyridyl)propyl]-3-(N,N-diethylamidino)- urea

Table I (continued)

1- 3-(3'-chloro-2'-pyridyl)propyl] -3-cyclopropylamidinourea 1- 3-(3'-chloro-2'-pyridyl)propyl]-3-cyclobutylamidinourea

1- 3-(3'-chloro-2'-pyridyl)propyl]-3-(N-[3'-cyclopentenyl3- amidino)urea

1- 3-(3'-chloro-2*-pyridyl)propyl] -3-cyclopropyImethyl- amidinourea 1- 3-(3'-chloro-2'-pyridyl)propyl] -3-me hoxyethylamidino- urea 1- 3-(3'-chloro-2*-pyridyl)propyl] -3-benzyloxyethyla idino- urea 1- 3-(3'-chloro-2'-pyridyl)propyl] -3-phenethoxyεthylamidino- urea

1- 3-(3*-chloro-2'-pyridyl)propyl] -3-benzylamidinourea

1- 3-(3'-chloro-2'-pyridyl)propyl] -3-(N/N-dimethylamidino)- urea

1- 3-(3'-chloro-2'-pyridyl)propyl] -3-(N,N-diethylamidino)- urea 1- 3-(3'-chloro-2'-pyridyl)propyl] -3-(N,N-tεtramethylene- amidino)urea 1- 3-(2'-pyridyl)propyl]-3- (N,N[3' -methyl-3'-azapentamethyl- enε]amidino)urea 1- 3-(2'-pyridyl)propyl]-3-(N,N[3' -oxapεn amethylene3- amidino)urea

1- 3-(3'-chloro-2*-pyridyl)propyl] -3-(N-[3 ^** -cyclopεntenyl3- amidinourea 1- 3-(3'-chloro-2'-pyridyl)propyl] -3-cyclopropylmethyl- amidinourea

1- 3-(3'-chloro-2'-pyridyl)propyl] -3-methoxyethylamidino- urea 3-(3'-chloro-2'-pyridyl) ropyl] -3-benzyloxyethylamidino- urεa

1- 3-(3*-chloro-2'-pyridyl)propyl] -3-phenethoxyethylamidi- nourea

1- 3- (3'-chloro-2'-pyridyl)propyl] -3-benzylamidinourea 1- 3- (3*-chloro-2'-pyridyl)propyl] ^• 3- (N/N-dimethylamidino)- urea

Table I (continued)

1- [3- (3 ' -chloro-2 ' -pyridyl) propyl] -3- (N,N-diε thy lamidino) - urea 1- [3- ( 3' -chloro-2' -pyridyl) propyl] -3- (N,N-tetramεthylene- amidino) urea

1- [3- (2 ' -pyridyl) propyl] -3- (.N,N [3 '-methyl-3 ' -azapentamethy- lene) amidino) urea 1- [3- (2' -pyridyl) propyl] -3- (N,N[3 '-oxapentamethylene]- amidino) urea 1- [3- (3 '-methyl-2 * -pyridyl) propyl] -3- (N,N-tetramethylene- amidino) urea 1- [3- (3* -methyl-2' -pyridyl) propyl] -3- (N,N-pen amethylene- amidino)urea 1- [3- (4 ' -pyridyl) ropyl] -3- (N-methyl-N-ethylamidino) rea 1- [3- (4' -pyridyl) propyl] -3- (N N-dimethylamidino) urea

1- [3- (4 '-pyridyl) propyl] -3- (N,N-diethy lamidino) urεa 1- [3- (3 ' -pyridyl) propyl] -3- (N,N-pentamethyle ^" neamidino) urea

1- [3- (3 '-chloro-2* -pyridyl); propyl] -3-methylamidinourea l-[3-(3 ^, -chloro-2* -pyridyl). propyl] -3-ethy lamidinourea

1- [3- (3 ' -chloro-2 ' - pyridyl ),p ropy 1] -3-propylamidinourea 1- [3- (3 * -chloro-2 ' - pyridyl). propyl] -3 -i-propy lamidinourea 1- [3- (3 ' -chloro-2 * - pyridyl).propyl] -3 -butyl amid inourea- 1- [3- (3 ' -chloro-2 ' - pyridyD.propyl] -3-i-butylamidinourea

1- [3- (3 ' -chloro-2 ' - yridyD.propyl] -3-t-bu tylamidinourea l-.[ 3- (3' -chloro-2'- pyridyl). propyl] -3-penty lamidinourea 1- [3- (3 * -chloro-2 ' - pyridyl).. propyl] -3-allylamidinourea 1- [3- (3 ' -chloro-2 ' —pyridyD.propyl] -3-propargylamidinourεa 1- [3- (3 ^« -chloro-2 * --pyridyl). propyl] -3-cyclopropylamidinoure

1- [3- (3 ' -chloro-2 ' - pyridyl) propy 1J -3- _C yclobutylamidinourea

OMP

Table I (continued)

1_ [3-/ 3* -chloro-2* -pyridyl); propyl] -3-methylamidinourea

* ^• - _• l-[3- (3 ' -chloro-2 * -pyridyl). propyl] -3-ethylamidinourea 1- [3- (3 * -chloro-2 ' - pyridyl),propyl] -3-propy lamidinourea 1- [3- (3 ' -chloro-2 ' - pyridyl). propyl] -3-i-propylamidinourea l-[3-(3 '-chloro-2*-pyridyl).propyl] -3-bu tylamidinourea l-[3- (3 ' -chloro-2 * - pyridyD.propyl ^] -3-i-bu tylamidinourea 1- [3- (3 ' -chloro-2 * - Pyridyl ⁾ _ _p ropy-l] -3-t-bu tylamidinourea 1-13- (3 * -chloro-2' -pyridyl). propyl] -3-pεntylamidinourεa 1- [ 3- ( 3' chloro-2*- yridyl) propyl] -3- _a llylamidinourea

1- [3- (3 * -chloro-2 ' —pyridyD.propyl] -3-propargylamidinourea 1-1.3- (2* -pyridyl) propyl] -3 -me thy 1 ami di nourea l-[3- (2* -pyridyl) propy IJ -3-ethylamidir.ourea l-[3- (2 * -pyridyl) propyl] -3 -propyl amidi nourea l-[ 3- (2* -pyridyl) propy IJ -3-i-proρylaπp d inourea _. l-[3- (2 ^* -pyricyl ⁾ .prc-pyϋ -3-bu ylamidinourea l-[3-(2*-i^ridyl ⁾ propyl] -3-i-butyl rnidinouroa 1 ^~ 3- (2 "-pyridyl). ^' ropyl] -3-mcthylamidinourca 1- [ 3- ( 2 ' -pyridyl) p ro py 1] - 3 - e th y 1 am i d i ncu a 1-13- (2 '-pyridyl) propyl) -3 -propy lami _d inourea l- ^[ 3- ⁽ 2 '-pyridyl ⁾ propyl] -3-i -propyl ami inourea l- ^[ 3- ⁽ 2'-pyridyl ⁾ _propyl ^] -3-bu tylami _d inourea ' l- ^[3 - ⁽ 2 ^* -pyridyl ⁾ propyl ^] -3-i-b yl _a mi _ά i r _. ourea

Table 1 (continued)

1- (2 ' -pyrxdylmethyl) -3-methylamidinothiourea 1- (2 * -pyridylmethyl) -3-ethylamidinothioύrea 1_ (2 ^, -pryidylmeth l) -3-propylamidinothiourea 1- (2 * -pyridylmethyl) -3-i-propylamidinothiourea

1- (2 * -pyridylmethyl) -3-bu ylamidinothiourea 1- ( 2 ' -pyridylmethyl) -3-i-bu ylamidinothiourea 1- (2 ' -pyridylmethyl) -3-pentylamidino thiourea 1- (2 * -pyridylmethyl) -3-propargylamidinothiourea

1- (2* -pyridylmethyl) -3-allylamxdino thiourea

1_ (2 * -pyridylmethyl) -3-me thoxyethylamidinothiourea .

1- (2 ' -pyridylmethyl) -3-benzyloxyethylamidinothiourea 1_ (2 * -pyridylmethyl) -3-phenethoxyethylamidinothiourea 1- ( 2 ' -pyridylmεthyl) -3- (N _/ N-dimethylamidino) thiourea 1- (3 * -methyl-2 ' -pyridylmethyl) -3-methylamidinc thiourea

1- (3 * -methyl-2 ^' * -pyridylmethyl) -3-ethylamidino thiourea 1- (3 ' -methyl-2 * -pyridylmethyl) -3-propylamidino thiourea 1- (3 ^* -methyl-2 ' -pyridylmethyl) -3-i-propylamidino thiourea 1- (3 * -methyl-2 ' -pyridylmethyl) -3-i-butylaraidino thiourea 1- (3 ' -methyl-2 ' -pyridylme thyl) -3-pen tylamidino thi ^' ourea

1- (3 ' -methyl-2 ' -pyridylmethyl) -3-allylaιnidinothiourea 1- (3 ' -methyl-2 ' -pyridylmethyl) -3-propargylamidinothiourea

1- (3 ' -methyl-2 ' -pyridylme thyl) -3-benzylaιr.idir.othiourea 1- (3 ' -chloro-2 ^* -pyridylmethyl) -3-benzylamidinothiourea 1- (3 ' -chloro-2 ^* -pyridylmethyl) -3-p _r opargylaιrά inotιιiourea

1- (3 ^* -chloro-2 ^* -pyridylmethyl) -3- _C yclopropyl _. ___ά _d inot _h iourea 1- (3 ^* -chloro-2 ^* -pyridylmethyl) -3- _C yclobutylamidinotlu.ourea

-58- ϊable 1 (continued)

1-(3 ^» -chl ro-2*-pyridylm _* ethyl)-3-methylamidinothiourεa

1- (3* -chloro-2* -pyridylmethyl) -3-ethylamidinothiourea 1- (3 ' -chloro-2 * -pyridylmethyl) -3-proρy lamidino thioure ^' a 1- (3 ' -chloro-2 ' -pyridylmethyl) -3-i-propylamidino thiourea 1- (3 ' -chloro-2 * -pyridylmethyl) -3-butylamidino thiourea 1- (3 * -chloro-2 ' -pyridylmethyl) -3-i-bu tylamidinothiourea 1- (3 ' -chlor -2 ' -pyrxdylmethyl) -3-t-b tylamidinothiourea ^• 1- (3 ' -chloro-2 * -pyridylmethyl) -3-pentylamidinc thiourea 10 1- (3 ^* -chloro-2' -pyridylmethyl) -3-allylamidino thiourea 1- ⁽ 2 '-pyridylmethyl) -3-me th l m dinothiourea 1- ^(2* -pyridylmethyl) -3-ethylamidino thiourea l- ⁽ 2'-pyridyl ^; r,ethyl ⁾ -3-propylamidir_othio-irea 1- ⁽ 2 ' -pyridyl methyl) -3-i-prcpylami _d ir _. otrπ curea - ¹⁵ - 1- ^(2* -pyridylmethyl) -3-bu ylamidinothiourea " 1- ^(2* - ^p yridylmethyl) -3-i-bu Lylanidino hiourea l- ⁽ 2' -pyridylmethyl) -3- (N,N-diethylamidino) thiourea 1- ⁽ 2 '-pyridylmethyl ⁾ -3- ⁽ N,N-tetramεthyleneamidino)tliourea 1- ⁽ 2' -pyridylmethyl) -3- (N^-pentamεthyleneamidino) thiourea ² 0 1- ⁽ 2 ^* -pyridylmethyl) -3- (N,N-hexamεthyleneami _d ino ₎ thiourea 1- ( '-pyridylmethyl) -3- (N I-3-d ethylamidirιo) thiourea l-(4 -ρyridyl.r.ethyl)-3- (N, -dielhylanidir.o) thiourea 1- (4 ^* -pyridyl e hyl) -3- {IJ-methyl-II-ethylamidino) thiourea 1- (3 ' -pyridylmethyl) -3- ⁽ N,N-pentamethyleneamidino)thiour _e a 25 1- ( ' -me thy 1-2 ' -pyridylmethyl) -3-

⁽ N,N— etra εthyleneamidino) thiourea 1- (3 ' -methyl-2 * -pyridylmethyl) -3-

( _N/ I-J-pen tame thy leneamidino) thiourea

1- (3 '-c _hl oro- 2' -pyridylmethyl) -3- _b enzyloxyethylami _d inothiourea

Table 1 (continued)

1- [2- (2 * -pyridyD.Ie hylJ -3-me thy lamidinothi.ourea l-[2-(2'-pyridyl).ethyl] -3-ethylamidinothiourea 1- [2- (2 * -pryidylϊ.ethyl] -3-propylamidinothiourea 1- [2- (2* -pyridyl) ethyl] -3-i-propylamidinothiourea

1- 12- (2 ¹ -pyridyl) ethyl! -3-bu tylamidinothiourea 1- [2- (2* -pyrxdyl) _. ethyl) -3-i-bu ylamidinothiourea l-[2-(2'-pyridyl).-.ethyl3 -3-pεntylamidinothiourea 1- [2- (2 * -pyridyl) ethyl] -3-propargylamxdinothiourea 1- [2- (2* -pyridyl)! ethy 13 -3-allylamidinothio.urea

1-1 - (2* -pyridyl). ethyl) -3-methoxyethylamidirothiourea ^* - 1- [2- (2 '-pyridyl.) -ethyl! -3-benzyloxyethylamidinothiourea 1- [2- (2* -pyridylmethyl) -3-phenet_hoxyethylamidir- hiourea, l-[2-(2'-pyridyl);ethyl] -3- (N,N-dimethylamidino)thiourea 1- 1 - (2 '-pyridyl) ethyl] -3- (N,N-diethylamidino) thiourea

1- [ -(2 '-pyridyl) ethyl] -3-me hyln idinotbiourea

1- [2 -(2 ^* -pyridyl) ethyl) -3-ethy amidinothiourea .

1~ 12- (.2 '-pyridyl) ethyl] -3-ρropylamidinothiourea

1- [2- (2 '-pyridyl) eth ll -3-i-proρylami nothio;urea 1- [2- (2' -pyridyl) etliyl] -3 -bu tylamidinothiourea

1- [2- (2 ^* -pyridyl) ethyl) -3-i-b ylam dinothiourea l-[2-(2'-pyridyl.):ethyl] -3- (N^-tetramethyleneamid ^' ino) thiourea l-[2-(2 ^, -pyridyl.I.ethyl] -3- (N,N-pentamethyleneamidino) thiourea 'l- [2- (2' -pyridyl) ethyl] -3- (N.N-hexamethylenea idino) thiourea 1_ j3_ (3« -pyridyl) propy ljr: 3÷. (ft , J-.pentametliylene- amidino ) thiourea

.-.-- OMPI

Table 1 (continued) l-(3 -pyrxdylmethyl 3- -t-butylamidino thiourea l-(3 -pyridylmethyl -3 -pen tylamidinothiourea l-(3 -pyridyImethy1 -3- -allylamidino thiourea l-(3 -pyridylmethyl -3 ^* -propargylamidino thiourea l-(3 -pyridyImeth l -3 ^* -cyclobuty lamidino thiourea l-(3 -pyridyImethyl -3- -cyclohεxylamidino thiourεa l-(3 -pyridylmethyl -3- -bεnzylamidino thiourεa l-(3 -pyridylmethyl -3- -mεthoxyethylamidinothiourea l-(3 -pyridylme hyl -3- -benzyloxyethylamidino thiourea l-(3 -pyridylmethyl -3- -methoxyethylamidino thiourea - l-(3 -pyridylmethyl -3- -benzyloxyεthylamidino thiourεa l-(3 -pyridyImethyl -3- -phεnεthoxyεthylamidinothio rεa l-(3 -pyridyImethyl -3- - (N/N-dimεth'ylamidino) thiourea l-(3 -pyridyImeth l -3- - (N/N-diethylamidino) thiourea ^" l-(4 -pyridylmethyl -3- ^■ methylamidinbthiourea l-(4 -pyridylmeth l -3- - ethylamidino thiourea l-(4 -pyridyImethyl -3- "Propylamidino thiourea l-(4 -pyridylmethyl -3- - i-propylamidino thiourea l-(4 -pyridylmethyl -3- -butylamidino thiourea l-(4 -pyridylmethyl -3- - t-butylamidino thiourea l-(4 -pyridylmethyl -3- - pεntylamidinc thiourea l-(4 -pyridylmethyl -3- - hexylamidino thiourea l-(4 -pyridylmethyl -3- - propargyla i _d inothiourea l-(4 -pyridylmethyl -3- ^■ allylainidinothiourea l-(4 -pyridylinethy1 -3- ^• methoxyethy lami inot iourea l-(4 -pyridylmethyl -3- - benzyloxye thylamid inoth iourea l-(4 -pyridy me hyl -3- - phenethoxyethylamidinothiourea

Table 1 (continued) 1-^32 - ₍ 3 '-pyridyl )ethyl] -3-t-butylamxdinothi.ourea

1- [2 - ₍ 3 ' -pyridyl ).ethyl] -3-pentylamidinothiourea 1- _[ 2 - ₍ 3 * -pyridyl ) ethyl] -3-allylamidinothiourea 1- [2 - (3 ' -pyridyl ) ethyl] -3-propargylamidincthiourea

1- [2 - ₍ 3 • -pyridyl ).ethyl] -3-cyclobutylamidinothiourεa l-[2 - ₍ 3' -pyridyl ).ethyl] -3-cyclohexylamidinothiou ^' r ^e a l-[2 - ₍ 3» -pyridy _). e h l] -3-benzylamidinothiourea ~I2 - ₍ 3' -pyridyl) ethyl] — 3-methoxyethylamidirιothiourea l-[2 -(3'-pyridyl).e hyl] -3-benzyloxyethylamidinothiourea l-[2 - ₍ 3 '-pyridyl). ethyl] -3-methoxyethylamidxnothiourea l-[ 2— ₍ 3 '-pyridyl) ethyl] — 3— benzyloxyethyla idinot iourea l-[2 - ₍ 3 '-pyr dyl) ethyl] -3-phenethoxyethylamidinothiourea l-[2 - ₍ 3 * -pyrxdyl) ethyl] -3- (N,N-dimethylamidino)thiourea l-[2 - ₍ 3 '-pyridyl) ethyl] -3- (N,N-diethylamidino)thiourea l-[2 -( '-pyridyl ⁾ ethyl] -3- methyl a ^' raidin thiourea 1-12.-(4 '-pyridyl) ethyl ^] -3- _e thylamidinothiourea l- ^[ 2 - (4 ' -pyridyl) ethylj -3-propylamidinothiourea l-[ ₂ -(4 '-pyridyl) ethyl] -3-i-propylamidinothiourea 1- [2 --(4 '-pyridyl) ethyl] -3-bu ylamidinothiourea ^• l-[2 -( '-pyridyl) ethyl] -3- _. t~butylamidincthiourea 1- [2 - (4 ' -pyridyl) .ethyl] -3- pentylamidinothiourea 1- [2.- (4 ' -pyridyl ⁾ e thyl ⁾ -3- hexylamidinpthiourea l-[2 - ( '-pyridyl) ethyl] -3- ropargylamidxnothiourea l-[2 -(4'-pyridyl) ethyl] -3- allylamidi othioύrea

1-1 -( '-pyridyl) ethyl) -3-mεthcxyethylamidino±hiourea.

abie 1 (continues), . ..„,-.„-.„, l-[3- ₍ 2'-pyridy _] )prc yll -3-uιethylanτ.axno tn ⁱ ourea

-3-ethylamidino t ^h iourea l-[3 - ₍ 2 '-pyridyl ₎ propyl] -3-propylamidino thiourea _l -[ ₃ - ₍₂ '-pyr5 _d y _l )pισr- _' yl3 -3-i-proρylaiftidi no t ^h io ^u r ^e a _l - _[3 - ₍₂ ' - _p yri _d y propyll -3-butylamidino thiour ^ea _l _ ₃ _ ₍₂ '- _py ri _d yDpropyl] -3-i- utylamΛdIno thiourea

1- [3 - (2 ' -pyridyl )propyl] -3-me thoxyethylamidino thiourεa 1- [3- (2 ' -pyridyl )propyl] -3-bεnzyloxyethylamidinothiourea 1- [3- (2* -pyridyl _. ) propyl] -3-phenethoxyethylamid__notiourea l-I ³ -(2'-pyridyl)propyl] -3- (N,N-d ime thy lamidino) thiourea 1- [3- (2' -pyridyl) propyl] -3- (N,N-diethylamidino)thiourea

1~J3 ^_ (2 * -pyridyl) ropylj -3-me hylamidinothiourea 1-13- (2* -pyridyl) propyl] -3-ethylamidinothiourea _ 1-1 ³ -( 2' -pryidyl) propyl] -3-propylamidinothiourea • -*-~ f ^"3 - (2 ^• -pyrxdyl )propyl] -3-i-propylamidinothiourea 1-13- (2 ' -pyridyl) propyl] -3-b tylamidinothiourea 1-12- ( 2' -pyridyl ⁾ ropyl] -3-±-butylamidinothiourea 1-13- (2* -pyridyl) propyl] -3-pentylamidino thiourea 1^-1.3 - (2 ' -pyridyl) propyl] -3-propargylamidino-thiourea 1- [3- (2 ' -pyridyl ) propyl) -3-allylamidino thiourea 1- _{[3~ (} 4 * - _p yridy 1) propyl] -3-methylamidin thiourea 1_ _[3 - » -pyri _d y _l ) propyl] -3- et _h y _l amidinc hiourεa l- _{[ 3} - ₍ 4* -pyridyl) propyl] -3-propylamidino thiourea _l - _{[ 3} - ₍ 4* -pyri _d y _l ) propyl] -3- -propylamidino thiourea 1- _[3 - ₍₄ » - _py ri _dyl ) propyl] —3- butyl amidino thiourea

OMPI

Table 1 (continued)

1- [2 - (3 ■ -methyl-2 ^» -pyridyl) ethyl] -3-

(N,N-tetramethyleneamidino) thiourea 1- [2 - (3 ' -methyl-2 ' -pyridyl) .ethyl] -3-

(N N-pentamethyleneamidino) ^thlourea 1- [3- (4 ' -pyridyl) propyl] -3- t-butylamidino thiourea 1- [3- ' -pyridy] ) propyl] -3-pentylamidinc thiourea l-[3-(4'-pyridyl)prcpyl] -3-hexylamidino thiourea 1_ [3- (4 ' -pyridyl) propyl] ~3~ propargylamidino thiourea ι_ [3- ( '-pyridyl) ropyl] -3-allylamidir.othiourea l-[ 3- ( '-pyridyl) ropyl] -3-methoxyethylamidincthiourea 1- [3- (4 ' -py idyl) propyl] -3- benzyloxy ethy lam dinothiourea 1- [3- (4 ' -pyridyl )pro: _J yll -3- phcnc thoxyethyla∑nidinctbioarea l-[3-(4*-p3'ri yl)pr :iyl3 -3- (N. - m t-:yla:πidi no) thiourea i-[3-(4'-pyridyl)p:o_ _. :yl] -3- (M,N-dio thy raidino) thiourea !_ [2_ (4 '-pyridyl) propyl] -3- (:;-π.ethyl-N-ethylamf dino) thiourea

OMPI

Table 1 (continued) -

3 - 1*3 - (3 ¹ -chloro-2 * -pyridyl) w propyl) -3-methylamidinothioure l-[3- (5' -chloro— 2 * -pyridyl )proρyl ⁾ -3-ethylamidinσthiourea l-[3- (3* -chloro-2 ^τ -py idyl. )propyl3 -3-propylaraidinothioure l-[3- ^' (3* chloro— 2 * — pyridy 1> ) propyl] — 3— -propylamidinothiourea l-[3- (3 ¹ -chloro-2 ^τ -pyridyl )propyl] -3-bu ylamidino thiourea l-[3- (3 ^f -chloro-2 * -pyr-idyl ) propyl] -3-i-butylamidinothio-urea

_* l-[3- (3' chloro-2 ¹ -pyridyl ) propyl] —3-t-bu tylamidinothiourea l-[3_ (3 ^* -chloro-2 * -pyridyl) propyl] -3-pentylaraidinothiourea l-[3_ (3' -chloro-2 ' -pyridy 1" ) propyl] -3- _a llyl amidino thiourea

l-[3- (3* -pyridyl) propyl] —3- t-butylamidino thiourea l-[3- (3' -pyridyl) propyl] — 3 -penty lamidino thiourea i-[3- (3* -pyridyl) propyl] -3-allylamidino thiourea - l-[3- (3* -pyridyl) propyl) —3— propargylamidino tiiourea l-[3- (3' -pyr idy 1) propyl] —3— cyclobu tylamidinothiourea l-[3- (3 ^f -pyridy l) _prθ pyl] -3-cyclohexy lamidino thiourea l-[3- (3' -pyr dyl) propyl] ^' — 3— bεnzy lamidino thiourea l-[3- (3* -pyr dy ) propyl] _. — 3-methoxyethylamidino thiourea l-[3- (3' -pyridy ) propyll — 3-benzyloxyethylamidinothiourea l-[3- (3' -pyridyl) propyl] -3— methoxyethy lamidinothiourea . l-[3_ (3' -pyridyl) propyl] — 3-benzyloxyethylamidino thiourea l-[3- (3* -pyridyl) propyl] -3 -ph ene thoxy e thy 1 amid in othiourea

^" ϊ-[3- (3* -pyrid l) propyl] —3- (N _/ N-dimεthylamidino)thiourea

1-13- (3* -pyridyl) propyl] -3-(N,N-diethylamidino) thiourea

3.1: LE 1-A

X may be oxygen or sulfur

R, R__ R,

ϊable 1-A (continued)

Cl

H -C ₂ H ₅

CH.

CH.

Table 1-A ^continued)

R_ ^R 5

H

Table 1-A (continued) R.

-CH.

N A H

\\

Table 1-A (contιnι_gsd)

R,

TABLE 2

Cl

Table 2 (continued) R__

o^ H H

H -CH.

N ^ζ

Table 2 (continued) R

H -C ₂ H ₅

>

- RE

C? H H

^C Λ -CH.

& **

ti* o tn

CH, -H -CH.

- CH. -K -C ₂ H ₅

CH, -CH. -CH.

CH.

II -CH.

<: _

R Rr

0 _^ H H

OMPI

_T ab _l e 2 (continued

« -CH.

CH ₂ - - ^c %

Table 2 Tcontinued)

R. R. R,

-CH. -CH. H ₂ -

^■ C V CH, C

OMPI

Table 2 (continued)

R,-

H -CH.

O - ^CH 2- ^CH 2-

Table 2 (continued)

R-

G- H -CH.

- -H -C ₂ H ₅

Table 2 (continued)

R _c

H -CH.

^Q -

O- -CH. -CH.

ti* o Ui

H "Vs

&

Amidinoureas can be used in the practice of this invention in the form of a pharmaceutically acceptable salt. For example, they may be readily converted to their nontoxic acid addition salts by customary methods used in the art. Nontoxic salts of this invention can be formed from the base amidi¬ nourea and an acid which is pharmacologically accept¬ able in the intended dosages. Such salts include those prepared from inorganic acids, organic acids, higher fatty acids, high molecular weight acids, etc. Exem¬ plary acids are hydrochloric acid, hydrobromiσ acid, sulfuric acid, nitric acid, phosphoric acid, methane sulfonic acid, benzene sulfonic acid, acetic acid, propionic acid, malic acid, succinic acid, glycolic acid, lactic acid, salicylic acid, benzoic acid, nicotinic acid, phthalic acid, stearic acid, oleic acid, abietic acid, etc.

Prophylactic and therapeutic compositions containing amidinoureas are effective against coccidial infections and are useful for the treatment of humans and animals. Preferred compounds have a combination of desirable properties. For example, they combine specificity of action, moderate duration of host reten¬ tion, and a high therapeutic index (therapeutic index is described as the ratio of the 50% suppressant dose to the 50% lethal dose) . Standardized screening tech¬ niques for the identification of active anti-coccidial compositions have been used to evaluate amidinoureas within the scope of the present invention. See, the in vitro screening method described by cDougald and Galloway, in "Eimeria tenella: Anticoccidial Drug Ac¬ tivity in Cell Cultures," Experimental Parasitology, Vol. 34, No. 2, p. 189-196 (1973).

Following standard procedures for ascertaining anti-coccidial activity, compounds of Formulae I and

II have been administered to chickens at varying levels in their feed. The following test procedures are useful for ascertaining the i _j vivo anti-coccidial activity of the amidinoureas.

Test I Determination of Anti-coccidial Activity Hubbard broiler cockerels obtained from a commercial hatchery are maintained in disease-free rooms with uniform heat and lighting and fed unmedicated ration until they are 12 days old. Distribution to treatment groups is on a weight basis to achieve equal groups. A culture of Eimeria recently isolated from a commercial poultry farm and containing mostly E. tenella is freshly propagated and assayed prior to use to assure pathogenicity.

Each of 8 treatments is replicated in 4 cages of 10 birds each. The drug is premixed in finely ground corn prior to mixing in a standard broiler starter ration. The treatments include groups of: uninfected unmedicated control chickens; infected, unmedicated control chickens; and infected birds treated with the test compound at 5, 15, 30, 60, 125 and 250 ppm. The replicates of each treatment are distributed so as to insure equal exposure to environmental variables. Medication is started 2 days before infec¬ tion. At 14 days old, the birds are infected using the pathogenic field isolate of E. tenella.- The birds are observed daily and any untoward effects of the drug or pathological signs are recorded. The test

is terminated 7 days postinoculation. The birds are weighed and weight is calculated for days 0-7 post- inoculation. Feed consumption is measured. A necropsy is conducted and lesion scores for coccidiosis lesions are recorded.

Test 2 Spectrum of Anti-coccidial Activity Broiler chicks from a commercial hatchery are assigned to treatments at 12 days of age. Medicated feeds and .water are given ad libitum throughout. After 2 days on feed, chicks are infected with coccidia by oral inoculation. Birds are weighed at the start and at termination, and feed consumption is recorded.

The treatment of the birds is as follows:

Treatment Inoculum Cages

Unmedicated Uninoculated 1, 2, 3 Unmedicated E. acervulins 4, 5, 6

Test compound, 60 ppm " 7, 8, 9 ft n 30 It It 10, 11, 12

If n 20 n It 13, 14, 15

If If 10 ^' H It 16, 17, 18

The test procedure is also conducted with coccidia species, E. maxima, E. necatrix, and E. tenella.

OMPI.

The following data is collected: ^"

1. Daily observations for untoward drug effects.

2. Record deaths twice daily and autopsy dead birds.

3. Weigh birds at the start (for randomiza¬ tion) at infection, and 7 days postinocula- tion.

4. Weigh feed issued and returned, and cal- culate feed consumption.

5. Record lesion amounts of birds killed on 7 day postinoculation.

Test 3

Nature of Anti-coccidial Activity Coccidiocidal v. Coccidiostatic

Three groups of 5 broiler chicks from a com¬ mercial hatchery are assigned at 12 days of age to the bottom cages of a Petersime battery and given ex¬ perimental rations. After two days on experimental - rations, all birds are infected with Eimeria tenella. One group of birds is unmedicated throughout the 15 day period of the experiment. Medicated feeds of one group are replaced by unmedicated feed on day 7 post¬ inoculation. Feces are collected on days 4-15 and examined for coccidia oδcysts. Oδcysts counts are made by standard techniques. Birds are moved to clean upper cages on days 7, 9, 11 and 13 postinoculation, to prevent reinfection.

Additional tests for the development of drug resistance and the mechanism of anti-coccidial action are also conducted to ascertain the scope of anti-coccidial action of the compounds.

OMPI

Tests show that amidinoureas in their free base form and in the form of their pharmaceutically acceptable salts are useful for both the prophylaxis and curative therapy of coccidiosis in poultry. The present invention can be used to treat single and multi- pie infections, that is, infections caused by a single species or by a combination of species.

Compounds defined above are readily absorbed into the blood stream from the stomach and intestines when taken orally, and therefore, the preferred method of treatment is to give the drug orally which is also the safest and most practical route of administra¬ tion. Optional modes can be used where, for example, the human or animal is not eating or cannot swallow or has difficulty in swallowing. Other methods of administration which permit the drug to be absorbed in the gastrointestinal tract or which deliver a solu¬ tion of the drug directly to the blood stream can be employed. T e method of administration may also vary depending on the purpose of administration. For example, use as a prophylaxis or preventive treatment, or as a pre-immunity suppressant, or as a treatment of infect¬ ed animals can require different methods of treatment and dosage forms easily formulated by those skilled in the art.

The dosage regimens in carrying out this invention utilizing the amidinourea compositions for suppression of coccidiosis are those which insure maximum therapeutic response. The average effective daily dose is betweem about 0.1 to about 15 mg/kg of body weight with about 1 to about 10 mg/kg of btfdy weight being preferred.

OMPI

Compositions useful in the practice of the present invention can be prepared in forms suitable for administration by compounding an effective single dose amount of the compound with known ingredients generally _c employed in the preparation of therapeutic compositions of the type which are provided as tablets, hard or soft capsules, lozenges, pills, powders, granules,aqueous or oily suspensions, oil in water or water in oil emul¬ sions, syrups and elixirs, and which can be taken orally. -J_ _Q The treatment of animals can be accomplished by incorporating an effective amount of the compound in the animal diet as a feed supplement or dissolved in the animals liquid intake. Amidinoureas for use in the practice of the present invention include compounds 5 which are nontoxic to the animal host, including poultry, when administered to the animal in the ani als feed diet in concentrations of about 5 to about 500 pp . Anti-coccidial non-toxic effects can be realized also for various of the amidinoureas when administered in o the animal feed diet in concentrations of about-20 to about 250 ppm.

Compositions intended for oral use may be prepared according to methods known generally in the art. Such compositions may contain one or more agents 5 selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents. In general, the composition will contain the active amidinourea ingredient in admixture with non-toxic pharmaceutically acceptable excipients. Exemplary _Q excipients are: interdilutants such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating or disintegrating agents, for example, maize, starch, and algenic acid; binding agents, for example, starch,gelatin, and acacia; and lubricating 5 agents, for example, magnesium stearate, stearic acid, and talc. Tablets may be uncoated or they may be coated by known techniques to make them more effective, for

exa ple ^" , to delay disintegration or absorption, or to make them more palatable, or for other reasons for which orally administered drugs have been previously provided in coated form. Formulations for oral use may also be present¬ ed as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate and kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with an oil medium, for example, arachis oil, liquid parafin and olive oil.

Aqueous solutions containing the active anti¬ coccidial amidinourea comprise a further embodiment of compositions according to this invention. Excipients suitable for aqueous suspensions may be employed, if desired. Such excipients include: suspending agents, for example, sodium carbox ethyl-cellulose, methyl- cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidine, gum tragacanth and gum acacia; and dispersing or wetting agents which may be a naturally occurring phosphatide, for example, lecithin, condensation products of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate,. condensation products of ethylene oxide with long-chain aliphatic alcohols, for example, heptadecaethylenoeoxy-cetanol, condensa¬ tion products of ethylene oxide with partial esters derived from fatty acids and a hexitol, for example, polyoxyethylene sorbitol monoleate, and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyoxyethylene sorbitan monoleate. The said aqueous suspensions may also contain one or more preservatives, for example, ethyl, or n-propγl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil, and coconut oil, or in a mineral oil, such as, liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing, suspending or wetting agent. Addi¬ tional excipients, for example, sweetening, flavoring and coloring agents may also be present.

The compositions for use in the practice of this invention may also be in the form of oil-in- water emulsions. The oily phase may be vegetable oil, for example, olive oil, arachis oils, and mineral oil, for example, liquid paraffin or mixtures thereof. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soya bean licithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan mono-oleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixers may be• formulated with sweetening agents, for example, glycerol, sorbitol and sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

OMPI

The pharmaceutical compositions may be in the form of a sterile injectionable preparation, for example, as a sterile injectable aqueous suspension. This suspension may be formulated according to available art methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above or others. This sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as an aqueous solution buffered to a pH of 4.0 to 7.0 and made isotonic with sodium chloride.

Further, the active amidinourea may be admini¬ stered alone or in admixture with other amidinoureas or with other agents having the same, similar or different pharmacological properties.

Other suitable pharmaceutical carriers for human use are described in Ξ. . Martin et al., "Reming¬ ton's Pharmaceutical Sc" 14th Ed., Mark Publishing Company, Easton, PA, 1965. Additionally, subcutaneous implants of anticoccidium compounds may be used^ See, U.S. Patent No. 4,159,322.

EXAMPLES The following examples show veterinary and pharmaceutical compositions containing active amidi- noureas for use in the practice of this invention and serve to illustrate the preparation thereof.

Example 1

(A) 25 g of (2,6-dichlorophenylamidino)urea and (B) 175 g of peanut oil are intimately mixed with each other. Portions of 200 mg each of said mixture are filled into soft gelatin capsulesthus containing 25 mg of the active phenylamidi- nourea compound. The capsules are suitable for ad inis-

O PI

tration to humans and small animals for the prophylactic or curative treatment of coccidial infections.

Example 2

Ten thousand tablets for oral use, each con- taining 50 mg of l-(2,6-dichlorophenylamidino)-3-n- propylurea are prepared from the following types and amounts of materials.

Ingredient Grams l-(2,6-dichlorophenylamidino) 500 -3-n-propylurea lactose U.S.P. 350 potato starch U.S.P. 346

The mixture is moistened with an alcoholic solution of 20 g of stearic acid and granulated through a sieve and added to the following mixture.

Ingredient Grams potato starch U.S.P. 320 talcum 400 magnesium stearate 500 lactose 64

The mixture is thoroughly mixed and compressed into tablets. The tablets are especially useful for human use.

Example 3

An elixir in which each 5 ml contains 50 mg of 1-(2,6-dimethylphenyl)-3-[(2-ρyridyImethyl)amidino] urea hydrochloride is prepared by diluting 750 ml of invert sugar with 100 ml of water and adding to this 0.3 g of benzoic acid and 10 g of 1-(2,6-dimethylphenyl)-3 -[2—'(pyridylmethyl)amidino)urea hydrochloride. One

" ϋHE

OMPI /,. WIPO

hundred ml of alcohol (U.S.P. containing 0.2 g of flavors) are added and water is added to a total volume of 1 liter. The solution is thoroughly mixed, filtered, and bottled. The preparation is useful for administering to humans, small animals and avians for prophylactic treatment in combatting coccidial infections.

Example 4

Capsules are prepared from

150 g of l-(4-bromo-2-chloro-6-methyl- phenyl)-3-methylamidinourea hydrochloride,

3 g magnesium stearate,

2 g of finely divided silica sold under the trademark CAB-O-SIL by Godfrey L. Cabot, Inc.,

Boston, MA, and

234 g of lactose. The ingredients are thoroughly mixed with each other and the mixture is filled in gelatin capsules. Each capsule contains 500 mg of the composition and thus

150 mg of 1-(4-bromo-2-chloro-6-methylphenyl)-3-methy1- amidinourea hydrochloride. The capsules can be ad¬ ministered to humans or small animals.

Example 5

Tablets are prepared from

100 g of 1-(2-chloro-6-methylphenyl)-3-ethy1- amidinourea hydrochloride,

20 g of corn starch, 14 g of calcium carbonate, and 1 g of magnesium stearate.

The active compound and starch are thoroughly mixed, moistened with a 10 percent gelatin solution, and gran¬ ulated by pressing through a No. 20 sieve. The gran¬ ules are dried,thoroughly mixed with calcium carbonate and magnesium stearate, and compressed into tablets,

OMPI

-105- each weighing about 125 mg and containing 100 mg. The tablets are suitable for administration to humans and small animals.

Example 6

A composition is prepared from

75 g of l-(2-chlorophenyl)-3-ethylamidinourea hydrochlo ide,

50 g of microcrystalline cellulose,

10 g of polyvinylpyrrolidine,

10 5 g of magnesium stearate, and

85 g of starch.

The active compound and cellulose are intimately mixed, moistened with a polyvinylpyrrolidine solution in water, and granulated by pressing through a No. 10 sieve.

Tc The dried granules are mixed with starch and magnesium stearate and are compressed to dragee cores, each weigh¬ ing 225 mg. The cores are now provided with an elastic subcoat of an aqueous sugar solution containing 60 g of powdered acacia, 60 g of powdered gelatin, and o 600 ^of sugar per liter of solution. Thereafter a dusting powder mixture of 180 ^* g of powdered sugar, 60 g of powdered starch, 1 g of powdered talc, and 1 g of powdered acacia is applied to the dragee cores. Coating with the gelatin subcoat and dusting are repeated 5 about five times. The thus treated cores are sugar coated in the coating pan with a 60 percent sugar solution. Sugar coating is repeated until each dragee weighs about 400 mg. The preparation is suitable for admini¬ stration to humans and small animals.

OMPI

Example 7

This example illustrates the utilization of a representative member of the compounds of the present invention as a coccidiostatic agent in an animal feed. In a manner similar to that described below, other compounds encompassed by the present invention may also be incorporated as active coccidiostatic agents into animal feeds.

A medicated poultry feed intended as a starter feed for broilers is prepared by blending about 0.005 percent by weight of l-(2-bromo-6-methylphenyl)-3-n- propylamidinourea in a basic poultry ration containing:

Ingredient Amount corn meal. No. 2 yellow, ground, g 1123 stabilized grease or vegetable oil, g 60 soybean oil meal (Low fiber content 50% 480 protein) , g corn gluten meal, g 50 fish meal, antioxidant treated, 60% protein, g 30 fish solubles, dried basis, g 10 meat and bone scraps, 50% protein, g 140 corn distillers dried solubles, g 50 alfalfa meal, 17% protein 100,000 A/lb 30 salt iodized, g 5 manganese sulfate, feed grade, g 0.75 zinc carbonate or oxide, g 0.25 riboflavin, g 3 vitamin B '12' 9 6 calcium pantotheante, g 5 niacin, g 30 stabilized vitamin A USP units 6,000,000 vitamin D ₃ , IC units 650,000 vitamin E acetate, IU 5,000 vitamin E (menadione sodium bisulfite) , g 2

DL-methionine or hydroxy analog, lb 1 antioxidant (ethoxyquin or butylated 0.25 hydroxy toluene) , lb

-._>imilar feeds can be prepared containing one or more of other of the active amidinourea compounds.

Example 8 Encapsulates of 1-(2,6-dimethylphenyl)-3- isopropyl amidinourea hydrochloride are prepared by the procedure of U.S. Patent No. 3,773,919 as follows. Poly-L-lactide (10 g) and 1 g of 1-(2,6-dimethylphenyl)- 3-isoproρyl amidinourea hydrochloride are mixed and warmed to the melting point of the lactide. The mixture is cooled and ground into powder. Two grams of the powder injected subcutaneously by syringe into a\ feed- lot cattle and sheep would expectably reduce oδcysts counts and increase weight gain rate.

Example 9 Encapsulates of 1-(2-bromo-6-methylphenyl)-

3—(methylamidino)urea hydrochloride are prepared following the procedure of U.S. Patent No. 3,523,906 as follows. Five g of the polycarbonate of 2,2-bis(4-hydroxyphenyl)- propane are dissolved in 50 cc of methyϊene chloride ^to prepare a solution. One g of salimonycin is dispersed in this solution. The solution is emulsified to fine droplets in 150 ml of ethylene glycol and the methylene chloride gradually evaporated. The solid microcapsules are collected by centrifuge and rinsed with water. When subcutaneously implanted in, feed-lot cattle and sheep, or cattle or sheep on pasture, there is obtained a reduction in fecal counts of coccidia oδcysts and improved weight gain rate.

As mentioned above, implants in the form of encapsulates release the amidinourea compound in an amount such that the blood contains 10-20- nanogram %. As shown in the examples, various types of encapsulates may be used, all of which may have varying rates of release of the compound, and, when taken with the varia- tion in sizes of animals, it can be readily realized

OMPI

that varying sizes in implants, will be required de¬ pending on the situation. In general, however, the size of the implant will vary from about 0.5 to about 4 g and, if necessary, multiple dosage forms may be administered to large animals such as cattle. The amount of amidinourea in the implant may vary from about 5 to 95 wt%. Encapsulates may be inserted through a slit in the skin or in the case of microcapsules, administered by injection equipment. Test results indicate that compounds falling within the scope of Formula IX below exhibit a good degree of activity:

wherein X is oxygen or sulfur and wherein R^ and R _g are as defined in Formula I above. ^' Representative compounds of Formula IX are exemplified below:

1-(2-chloro-6-methylphenyl)-3-[ (2 ^» ,2* ,2 ^« -trifluoroethyl) amidino]urea;

1-(2,6-dimethylphenyl)-3-methyla idinourea;

1-(2,6-dimethylphenyl)-3-(3-methybutoxy)amidinourea; 1-(2,6-dijnethylphenyl)-3-(n-propylamidino)urea;

1-(2,6-dimethylphenyl)-3-ethylami inourea;

1-(n-propylamidino)-3-(2,4,6-trimethylphenyl)urea;

1-(4-trifluoromethylphenyl)-3-n-proρylamidinourea;

1-( c<_-napthyl)-3-methylamidinourea; 1-(2,6-dimethylphenyl)-3-isobutylamidinourea;

1-(2-chloro-6-methylphenyl)-3-methylamidinothiourea; l-(2-methylphenyl)-3-ethylamidinourea; .

1-(2-trifluoroethylphenyl)-3-ethylamidinourea; and

1-[2-(5-chloropyridyl)]-3-methylamidinothiourea. As is known, the literature includes reports that various amidinoureas. are effective for treating certain diseases in animals, including man. For example, it has been reported that various amidinoureas are effective in treating diarrheal disorders in mammalian species. However, it has not heretofore been known

OMP

that amidinoureas are effective in treating coccidiosis. As noted above, there are many other classes of compounds that have been reported for use as anti-coccidial agents. Typically, such anti-coccidial agents are administered to animals in feed supplements along with other materials including, for example, nutrients and other medicaments.

In the practice of the present invention, the source of effective anti-coccidial dose can be solely an amidinourea or mixture of amidinoureas. According to conventional practices, the anti-coccidial amidinourea can be administered to animals in a feed supplement along with other materials, for example, nutrients and other medicaments.

Alternatively, the anti-coccidial amidinourea can be used in combination, for example, in admixture, with other anti-coccidial agents. Thus, the present invention can be practiced by including in the animal's diet an effective anti-coccidial dose of a combination of individually ineffective coccidiostatic doses of ^a π amidinourea and other anti-coccidial agent. „

In view of the above, it should also be appre¬ ciated that the present invention encompasses within its scope the formulation of an animal feed supplement containing other materials in combination with an amidinourea as the sole effective anti-coccidial agent, or amixture of individually ineffective coccidiostatic doses of an amidinourea and other anti-coccidial agent, as an effective anti-coccidial medication.

In summary, it can be stated that the present invention provides an important advance in the art characterized by a number of advantages which flow from its use. Amidinoureas within the scope of the present invention exhibit relatively high activity

"ξTURlX

OMPI

when used in doses well below their toxic doses. Thus, the use of such amidinoureas do not require the strict control of the type required by currently used anti¬ coccidial compounds which are highly toxic. In addi- tion, amidinoureas within the scope of the present invention do not give rise to the animal tissue residue problem associated with other anti-coccidial agents, the use of which must be terminated weeks prior to the animal's slaughter. Amidinoureas within the scope of the present invention can be continuously used in the animal's diet up to the time of slaughter of the animal or a few days prior to slaughter.

OM